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RESUMEN 
  
Las enfermedades cardiovasculares (ECV) son la causa principal de morbimortalidad en el mundo 
debido en gran parte al envejecimiento progresivo de nuestras sociedades. El deterioro cardiovascular 
está acelerado en un trastorno genético muy raro llamado síndrome de progeria Hutchinson-Gilford 
(HGPS). Esta enfermedad está causada por una mutación puntual de novo en el gen LMNA, que conduce 
a la expresión de “progerina”, una forma mutante de la lamina A que provoca numerosas anomalías 
estructurales y funcionales en el núcleo. Los niños con HGPS presentan síntomas de envejecimiento 
prematuro, incluyendo alopecia, osteoporosis, lipodistrofia, rigidez de las articulaciones, arrugas de la 
piel y moteado, siendo la característica más importante de la enfermedad la aterosclerosis acelerada, 
proceso que conduce a muerte prematura a una edad media de 14,6 años, predominantemente por 
infarto de miocardio o accidente cerebrovascular. Existe un gran desconocimiento sobre los 
mecanismos por los que la progerina acelera la aterosclerosis, en gran parte debido a la falta de modelos 
animales adecuados. En esta tesis hemos generado nuevos modelos de ratón que permiten estudiar la 
aterosclerosis asociada a HGPS. Comparado con controles con el gen Lmna intacto, los ratones 
mutantes que expresan progerina de forma ubicua presentan envejecimiento prematuro asociado con 
pérdida de peso corporal y menor longevidad. Además, mostraron patología vascular similar a la 
observada en pacientes HGPS, incluyendo aterosclerosis acelerada, pérdida de células de músculo liso 
vascular (CMLVs), aumento del contenido de colágeno, retención de lípidos en la capa media y fibrosis 
de la capa adventicia. También hemos demostrado que los ratones que expresan progerina 
específicamente en CMLVs, pero no en macrófagos, recapitulan la patología vascular del modelo 
ubicuo. Además, tanto en el modelo ubicuo como en el específico de CMLVs, los ateromas mostraron 
evidencia de ruptura de la placa que podría provocar infarto de miocardio. Por otra parte, mediante 
transcriptómica de alto rendimiento identificamos en ambos modelos de ratón el estrés de retículo 
endoplásmico (RE) y la respuesta a proteínas desplegadas como posibles mecanismos inductores de 
muerte de CMLVs y aterosclerosis acelerada. De acuerdo con esta hipótesis, el tratamiento con ácido 
tauroursodeoxicólico (TUDCA), una chaperona química que aumenta la capacidad celular para 
soportar el estrés de RE, disminuyó en ambos modelos la aterosclerosis, la pérdida de CMLVs y el 
grosor de la adventicia. TUDCA también prolongó en un 35% la supervivencia de los ratones con 
expresión de progerina específica en CMLVs. En resumen, nuestros resultados sugieren el uso de 
TUDCA para prevenir la aterosclerosis y eventos cardiovasculares asociados a HGPS. Dado que la 
progerina se acumula con la edad en individuos sin HGPS, nuestros resultados también podrían arrojar 
luz sobre el envejecimiento fisiológico. 
  
SUMMARY 
  
Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide due to the 
progressive aging of our societies. Age-related decline in cardiovascular health is accelerated in a rare 
genetic disorder called Hutchinson-Gilford progeria syndrome (HGPS). The disease is caused by a de 
novo point mutation in the LMNA gene, which leads to the expression of “progerin”, a mutant form of 
the nuclear protein lamin A. Since lamin A possesses important structural and functional properties, 
progerin expression triggers numerous nuclear abnormalities. Children with HGPS exhibit premature 
aging symptoms, including alopecia, osteoporosis, lipodystrophy, joint stiffness, and skin wrinkling 
and mottling. However, the most clinically relevant feature of the disease is accelerated atherosclerosis, 
which leads to premature death at an average age of 14.6 years, predominantly from myocardial 
infarction or stroke. The mechanisms through which progerin provokes enhanced atherosclerosis 
remain poorly understood, in part due to the paucity of suitable models. To address this, we sought to 
generate new mouse models that allow the study of atherosclerosis in the context of HGPS. When 
compared with control mice expressing wild-type lamin A/C, mice with ubiquitous progerin expression 
exhibited a premature aging phenotype, including reduced body weight and shortened survival. In 
addition, progerin-expressing mice showed increased atherosclerosis burden together with a severe 
vascular pathology, including the depletion of vascular smooth muscle cells (VSMCs), increased 
collagen content, medial lipid retention and adventitial fibrosis, resembling most aspects of CVD 
observed in HGPS. We also found that mice expressing progerin specifically in VSMCs, but not in 
macrophages, fully recapitulated the vascular pathology observed in the ubiquitous progeria model. 
Atheromas of both ubiquitous and VSMC-specific models showed evidence of plaque disruption, 
which might lead to myocardial infarction. Using a transcriptomic approach, we identified endoplasmic 
reticulum (ER) stress and the unfolded protein response as possible driver mechanisms of progerin-
induced VSMC death and accelerated atherosclerosis. Accordingly, treatment with 
tauroursodeoxycholic acid (TUDCA), a chemical chaperone that increases the capacity of a cell to 
sustain ER stress, was effective at ameliorating vascular disease (atherosclerosis, VSMC loss and 
adventitial thickening) in both ubiquitous and VSMC-specific mouse models. TUDCA also prolonged 
the survival of mice with VSMC-specific progerin expression by 35%. Taken together, these findings 
indicate that TUDCA may be effective in the treatment of atherosclerosis and associated cardiovascular 
events in HGPS. Moreover, since progerin accumulates with age in non-HPGS individuals, our data 
may also shed some light on the mechanisms of normal aging. 
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I.1. Physiological aging and cardiovascular disease (CVD) 
I.1.1. Aging as a risk factor for CVD 
Aging is the main risk factor for the development of CVD (1). Although much progress has 
been made in the prevention, diagnosis, and treatment of CVD, it remains the leading cause of death 
worldwide (2). According to the World Health Organization, approximately 17.5 million people die 
annually from CVD, representing 31% of all deaths (www.who.int/cardiovascular_diseases). CVD is 
the outcome of complex interactions between modifiable and non-modifiable risk factors (3). Many 
modifiable risk factors for CVD have been identified, and the causal relevance of several of these 
factors is now well proven, including tobacco exposure, physical inactivity, obesity, hypertension, 
hypercholesterolemia and diabetes. Non-modifiable risk factors include age, gender, ethnicity and 
genetic susceptibility to the disease (family history). 
Age-related changes in the vasculature include luminal dilatation and arterial wall thickening, 
especially of the intima (e.g. atherosclerosis), leading to increased vascular stiffness (1, 4). Various 
changes in the vessel wall that show causal relationships with arterial stiffening have been described, 
including calcification, augmented content and crosslinking of collagen fibers, increased elastin 
breakage, and diminished elastin content (5-8). Moreover, endothelial function is impaired with age, 
further contributing to the reduced vascular compliance (1), defined as the capacity of a blood vessel 
to enlarge and contract in response to changes in the pressure. 
 
I.1.2. Atherosclerosis  
 Atherosclerosis underlies most manifestations of CVD, including coronary heart disease and 
cerebrovascular disease, and can lead to myocardial infarction or stroke. Atherosclerosis is 
characterized by thickening of the arterial wall and luminal narrowing due to atherosclerotic plaque 
buildup. The disease is initiated by endothelial dysfunction triggering low-density lipoprotein (LDL) 
infiltration and accumulation in the intima, principally at sites with disturbed blood flow (9). The 
presence of proteoglycans in the subendothelial space can further increase the retention of LDL 
particles (10), which are subsequently oxidized by reactive oxygen species. Oxidized LDL induces 
endothelial activation, which is characterized by the expression of adhesion molecules and the secretion 
of chemokines that trigger the recruitment of monocytes to the intima and their differentiation into 
macrophages. Neointimal macrophages begin to ingest modified LDL via the scavenger receptor 
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pathway (11), leading to their transformation into foam cells that secrete pro-inflammatory molecules, 
recruiting more immune cells to the lesion site. Impairment in the processing of oxidized lipoproteins 
leads to foam cell death (12). Progressive accumulation of cell debris and cholesterol crystals results 
in the formation of a necrotic core. Growth factors and cytokines present within the lesion induce the 
phenotypic transition of vascular smooth muscle cells (VSMCs) from a “contractile” to a “synthetic” 
state, and their migration from the media to the growing neointimal lesion. Neointimal synthetic 
VSMCs proliferate and abundantly synthesize extracellular matrix, normally stabilizing plaques. 
Mature fibroatheromatous plaques have a collagen- and VSMC-rich fibrous cap covering the necrotic 
core, which prevents its rupture and the subsequent life-threatening thrombus formation. 
 Plaque destabilization, including plaque rupture, plaque erosion and the formation of calcified 
nodules, is a complex process that depends on both structural features and biomechanical forces. Plaque 
rupture, which is the best characterized and the most common manifestation of plaque destabilization, 
is characterized by fibrous cap disruption and the ensuing exposure of the necrotic core to blood 
constituents, resulting in thrombus formation. Plaque destabilization may also occur due to plaque 
erosion and the accumulation of calcified nodules. Atherosclerotic lesions that are prone to rupture are 
termed “vulnerable” plaques, and are usually characterized by large necrotic cores, thin fibrous caps 
(related to decreased collagen and VSMC content), intraplaque hemorrhage, neoangiogenesis and large 
inflammatory infiltrates (13). Since plaque disruption can lead to myocardial infarction or stroke, it is 
of considerable importance to characterize and detect vulnerable plaques in order to prevent 
cardiovascular events in patients.  
 
I.2. Premature aging and CVD 
I.2.1. Hutchinson-Gilford progeria syndrome (HGPS) 
HGPS is an extremely rare disorder characterized by signs of premature aging. This devastating 
disease was first described by Jonathan Hutchinson in 1886 and Hastings Gilford in 1897 (14, 15). The 
prevalence of HGPS is 1 in 20 million and it has no ethnic or gender bias (16). Affected children are 
normal at birth but within the first two years of life they begin to present the first symptoms of the 
disease, such as failure to thrive and skin abnormalities. Patients progressively develop other signs of 
premature aging, including alopecia, mottled and wrinkled skin, loss of body fat, joint stiffness and 
osteoporosis (16, 17). Importantly, they show generalized atherosclerosis, which leads to death from 
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myocardial infarction or stroke at an average age of 14.6 years (18). While HGPS resembles most 
aspects of normal aging, patients do not show signs of neurodegenerative disease or cancer. 
 
I.2.2. CVD in HGPS 
The most clinically relevant feature of HGPS is atherosclerosis, which is responsible for more 
than 90% of deaths (16). Atherosclerosis in HGPS is particularly intriguing because patients lack the 
classical risk factors for CVD development, such as hypercholesterolemia and increased serum C-
reactive protein (19). Although levels of athero-protective high-density lipoproteins (HDL) are similar 
between prematurely-aged and healthy children, there is an age-dependent decline in HDL levels in 
HGPS (19). Autopsy findings have revealed that patients with HGPS present a wide spectrum of plaque 
phenotypes, ranging from early to late stage (20). These atherosclerotic lesions usually exhibit 
calcification, inflammation, and evidence of plaque erosion or rupture, similar to what is observed in 
physiological aging (20). The overall absence of pronounced dyslipidemia in progeria could partially 
explain why HGPS lesions tend to have smaller atheromatous cores than those of typical age-associated 
atheromas (20). 
The severity of atherosclerosis in progeria usually correlates with VSMC depletion in the media 
(21, 22). This severe loss of VSMCs is accompanied by extracellular matrix deposition and altered 
elastin structure (20-22). In contrast to what is seen in normal aging, HGPS arteries and veins present 
prominent thickening of the adventitia (20), which together with VSMC loss may result in vessel 
stiffening and reduced vascular compliance, triggering plaque development. Accordingly, patients with 
HGPS exhibit an increase in both carotid-femoral pulse wave velocity and arterial wall echodensity, 
confirming that vascular stiffening is an essential contributor to cardiovascular decline in progeria (23). 
Aortic stiffness can then lead to augmented afterload and the subsequent left ventricular hypertrophy 
observed in some HGPS patients (16, 17, 20, 22). 
The ability of blood vessels to stretch in response to changes in the pressure plays an important 
role in the regulation of blood pressure. Although some authors reported development of hypertension 
in HGPS subjects, it does not seem to be a generalized symptom of the disease. Merideth et al. described 
elevated systolic or diastolic blood pressures in 7/15 patients as compared with both age- and height-
matched healthy controls (17). However, they reported only the highest reading even though blood 
pressure was measured an average of six times during the course of the study, which questions the 
validity of their results and conclusions. Further work by Gerhard-Herman et al. reported increased 
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systolic pressure in 7/26 patients and increased diastolic pressure in 9/26 patients as compared with 
age-matched controls (23). When they applied height-age standards to account for the growth 
impairment, systolic and diastolic blood pressures were higher in approximately half of the patients. 
Nonetheless, pulse pressure, which is defined as the difference between systolic and diastolic blood 
pressure and positively correlates with CVD risk during physiological aging (24, 25), was within the 
normal range for both chronologic age and height age (23). Of note, none of the studies analyzed 
hypotension incidence in HGPS, albeit raw data from some reports clearly show that some blood 
pressure measurements are below the normal range for the age-matched controls (20). 
These somewhat contradictory observations on blood pressure may in fact indicate that progeria 
patients have blood pressure instability and variability, which has been recently shown to be a strong 
predictor of stroke (26, 27). This could be of special relevance for HGPS because arterial ischemic 
strokes are common during the disease progression and may lead to death in about 10% of patients 
(18). A retrospective study by Silvera et al. found evidence of stroke in 60% of patients, of which half 
was clinically silent (28). Likewise, vascular alterations in the brain, including intracranial and distal 
vertebral artery steno-occlusive disease with collateral vessel formation, are frequently found in HGPS 
(28). Remarkably, this arteriopathy is different from other vasculopathies of childhood and 
cerebrovascular disease during physiological aging (28). In spite of evident vascular alterations in the 
brain, progeric patients have normal cognitive function with the exception of stroke-related defects (16, 
29). 
While stroke accounts for some mortality in HGPS, the most common cause of death is 
myocardial infarction. As in the case of stroke, patients may have clinically silent myocardial infarcts 
during their lifetime (16). Indeed, autopsy findings provided evidence of remote (months), subacute (2-
3 weeks), and acute (2-3-day-old) myocardial infarctions in the same patient (20). These acute and 
chronic infarcts may lead to arrhythmia and death. In a recent study, Rivera-Torres et al. showed age-
related repolarization abnormalities in HGPS patients, manifested as ST segment depression/elevation 
and negative or biphasic T waves on the electrocardiogram (ECG), which can lead to an increased risk 
of arrhythmias (30). Another study also reported age-related ECG abnormalities in some patients, such 
as prolonged QT interval (17). Cardiac electrical defects in HGPS may be a consequence of heart 
fibrosis caused by non-fatal infarcts as well as valvular dysfunction. Likewise, various studies 
described severe degenerative aortic and mitral valvular disease in HGPS, characterized by thickening, 
fibrosis and calcification of the valve leaflets (16, 17, 20, 31, 32). 
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In summary, HGPS patients present severe cardiovascular defects in the vessels, heart, brain 
and valves, which resemble many aspects of physiological aging. Thus, progeria is a model of 
cardiovascular aging isolated from classical cardiovascular risk factors and may enhance our 
knowledge about the initiation and progression of vascular stiffening, atherosclerosis and the incidence 
of cardiovascular events. 
 
I.2.3. Mechanism leading to progerin production 
HGPS is caused by a heterozygous de novo point mutation within the LMNA gene (33, 34). In 
normal cells, alternative splicing of the LMNA gene gives rise to two major isoforms, lamin A and 
lamin C (35). Some minor forms are also produced, such as lamin A10 and the germline-specific 
lamin C2 variant (36, 37). Lamin A and lamin C are expressed in the majority of differentiated somatic 
cells, and play important roles in maintaining nuclear structure and function (38). 
Various posttranslational modifications of prelamin A (664 amino acid residue) give rise to 
mature lamin A (646 amino acid residue) (Fig. 1). First, the CaaX motif located at the C-terminus of 
prelamin A is farnesylated by farnesyl protein transferase (39, 40). Next, the last three residues (-aaX) 
are removed usually by the zinc metallopeptidase STE24 (ZMPSTE24), also known as farnesylated 
proteins-converting enzyme 1 (40). The newly exposed C-terminal cysteine is then carboxymethylated 
by isoprenylcysteine carboxylmethyltransferase (ICMT) (40). These modifications are believed to 
enhance hydrophobic interactions with the inner nuclear membrane and to facilitate assembly into the 
nuclear lamina (41). Finally, ZMPSTE24 cleaves the last 15 amino acids together with the farnesyl and 
carboxymethyl groups (after tyrosine in position 646), resulting in mature lamin A (42-44). 
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Figure 1. Lamin A maturation. Lamin A is formed from a precursor termed prelamin A. Prelamin A is first farnesylated 
by a farnesyltransferase (FT) on the cysteine residue within the CaaX motif (where “C” is cysteine, “a” is an aliphatic amino 
acid, and “X” is variable, in case of prelamin A: CSIM). Next, the C-terminal tripeptide (–SIM) is removed, usually by 
ZMPSTE24, a zinc metalloendoprotease. This is followed by carboxymethylation of the newly-exposed cysteine by 
isoprenylcysteine carboxylmethyltransferase (ICMT). Finally, the last 15 amino acids containing the farnesyl and 
carboxymethyl modifications are cleaved by ZMPSTE24, resulting in mature lamin A. 
 
 “Classical” HGPS is caused by a single nucleotide substitution in exon 11 (c.1824C>T; 
p.G608G) (33, 34). This cytosine-to-thymine substitution does not change the amino acid encoded 
(both GGC and GGT codons encode glycine), but activates a cryptic splice site leading to a deletion of 
150 nucleotides in the mRNA. This aberrant splicing results in the production of a truncated form of 
lamin A, referred to as progerin, missing 50 amino acids close to the C-terminus. Progerin lacks the 
cleavage site for ZMPSTE24 and therefore retains the last 15 residues together with farnesyl and 
carboxymethyl groups. Permanently farnesylated and carboxymethylated progerin stays anchored in 
the inner nuclear membrane, leading to abnormalities in the nuclear shape and function (45, 46). 
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I.3. Progerin and prelamin A in physiological aging 
Under normal conditions, prelamin A is almost undetectable in cells because it is rapidly 
processed into mature lamin A after translation. Farnesylated prelamin A accumulation due to 
inactivating mutations in the ZMPSTE24 gene also leads to progeria-like syndromes, such as restrictive 
dermopathy (47-49) and mandibuloacral dysplasia (50). Remarkably, increased amounts of prelamin 
A have been also observed during physiological aging, presumably due to an age-dependent 
downregulation of ZMPSTE24 (51). Interestingly, inhibitors of proteases used for human 
immunodeficiency virus treatment result in increased levels of prelamin A and accelerated vascular 
aging (52, 53). 
Many studies revealed that non-HGPS individuals accumulate small amounts of progerin with 
age (20, 54, 55). One possible explanation for this is because in healthy subjects the cryptic donor splice 
site shares 5 of 7 bases with the consensus splice sequence, leading to sporadic usage of the splice site. 
In HGPS, the cryptic donor splice site shares 6 of 7 nucleotides with the consensus splice sequence due 
to the C-to-T substitution, resulting in the frequent occurrence of aberrant splicing. 
Thus, the accumulation of permanently farnesylated prelamin A and progerin in both normal 
and premature aging strongly suggests that some mechanisms are shared between these physiological 
and pathological processes. Accordingly, conclusions derived from the study of progeria may also shed 
some light on normal aging. 
 
I.4. Mouse models of progeria 
As of 1st April 2017, there were 148 identified children living with progeria worldwide 
(www.progeriaresearch.org). Of these, 115 carry the HGPS classical mutation, and the remaining 33 
children have a mutation within the lamin A pathway but do not express progerin. This extremely low 
number of HGPS patients leads to challenges in conducting both clinical trials and research on the 
mechanisms driving the disease. Because of this, various mouse models of progeria have been created 
over the past 15 years that resemble many, but not all, premature aging features. This may be in part 
attributed to interspecies differences (e.g., in lipid metabolism) and distinct toxicity of progerin in mice 
and humans. Furthermore, the differences in the phenotype between different mouse models may be a 
consequence of diverse strategies used during their generation, which lead to variable progerin levels, 
as well as the absence or presence of other Lmna gene products, such as lamin A and lamin C. 
I. INTRODUCTION 
16 
 
The first progerin-expressing mouse model was developed by Yang et al. in 2005. The authors 
created a mutant allele called LmnaHG (“Hutchinson-Gilford”) that, unlike in the human disease, gives 
rise exclusively to progerin (56, 57). Heterozygous LmnaHG/+ mice, which express progerin from the 
mutant allele and lamin A/C from the wild-type allele, showed reduced weight gain around 6-8 weeks 
of age and died by 4-6 months of age (compared with a lifespan of more than 2 years for wild-type 
mice). Homozygous LmnaHG/HG mice expressing solely progerin presented a more severe aging 
phenotype and died by 3-4 weeks of age. Both, LmnaHG/+ and LmnaHG/HG mice displayed some of the 
symptoms common to HGPS, such as hair loss, osteoporosis, loss of subcutaneous fat, but no 
cardiovascular alterations were observed (57). 
Varga et al. generated a transgenic mouse model by introducing a bacterial artificial 
chromosome (BAC) containing the human LMNA gene carrying an HGPS-causing mutation 
(c.1824C>T; p.G608G) (58). In addition to the mutated LMNA gene, the BAC also contained RAB25 
(coding for another isoprenylated protein), UBQLN4 and MAPBPIP genes. In consequence, G608G 
BAC mice expressed mouse endogenous lamin A/C together with human progerin and 3 other human 
proteins. While these mice did not present any evident signs of premature aging, progressive VSMC 
depletion was observed in the media, beginning at 5 months of age. Reduced VSMC number was 
accompanied by an increased deposition of collagen and proteoglycan in the media, altered elastic fiber 
structure, and thickened adventitial and medial layers. Remarkably, the vascular pathology was similar 
to that observed in HGPS (20-22). In line with the aortic phenotype, vascular responsiveness to sodium 
nitroprusside administration was decreased in G608G BAC mice. Nevertheless, no evidence of 
atherosclerotic plaque formation was found (58). 
LmnaHG and G608G BAC mice fail to fully recapitulate the human disease, showing only 
premature aging or vascular alterations. Thus, Osorio et al. created a knock-in mouse model harboring 
a c.1827C>T (p.G609G) mutation within the mouse Lmna gene, which is equivalent to the human 
c.1824C>T (p.G608G) HGPS-causing single nucleotide substitution (59). Similar to what is observed 
in HGPS, the presence of the LmnaG609G allele leads to the synthesis of progerin via aberrant splicing, 
together with lamin C and some residual lamin A. Homozygous LmnaG609G/G609G mice showed growth 
retardation after 3 weeks of age and died at an average age of 15 weeks. They also presented a loss of 
subcutaneous fat, attrition of hair follicles, and bone alterations. Notably, LmnaG609G/G609G mice 
presented VSMC depletion in the medial layer of the aortic arch, but not of the thoracic aorta. Despite 
the loss of VSMCs, no changes in the blood pressure were detected; however, animals developed age-
dependent bradycardia. Moreover, prolonged QRS duration was observed on the ECG, indicating 
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alterations in cardiac conduction. Heterozygous LmnaG609G/+ mice appeared normal until 8 months of 
age, when they started presenting an aging-phenotype similar to that of homozygotes, and died at an 
average age of 35 weeks. Remarkably, LmnaG609G/+ mice developed severe calcification of the aortic 
media (60), a relevant symptom observed in HGPS. In summary, whereas LmnaG609G/G609G mice 
recapitulate most of the clinical features of progeria, atherosclerosis has not been reported. 
Lee et al. have recently created a new LmnaG609G/G609G mouse model that, similar to the model 
developed by Osorio et al., harbors an HGPS-causing mutation in the Lmna gene that yields progerin 
via abnormal splicing (61). Homozygous LmnaG609G/G609G mice display a phenotype similar to that of 
other formerly described progeria models (43, 57, 59, 62), including VSMC depletion in the media of 
the ascending aorta and adventitial fibrosis by 4 month of age. No detailed examination of the other 
phenotypical characteristics was provided by the authors (61). 
Other important models of premature aging are Zmpste24-deficient mice, which were generated 
in parallel by two different groups (43, 62). These mice accumulate permanently-farnesylated prelamin 
A due to a loss of function of the metalloproteinase involved in lamin A maturation. The Zmpste24-/- 
mouse model created by Bergo et al. showed growth impairment, decreased subcutaneous fat content, 
alopecia, muscle weakness and bone abnormalities, and died at 6-7 months of age (62). Zmpste24 null 
mice generated by Pendas et al. presented a slightly more severe phenotype, characterized by growth 
delay, lipodystrophy, alopecia, skeletal and muscular atrophy, cardiac abnormalities (heart interstitial 
fibrosis, thinning of the ventricular wall and dilatation of both ventricles), and death at an average age 
of 5 months (43). Consistent with the cardiac phenotype described by Pendas et al. (43), recent studies 
revealed electrical cardiac alterations in Zmpste24-deficient mice (30).  
 
I.5. General mechanisms of HGPS 
Lamin A plays important roles in a wide variety of cellular functions, ranging from maintaining 
the mechanical stability of the nucleus to regulating gene transcription and signal transduction (38). 
Accordingly, accumulation of progerin and prelamin A may trigger the disease through various non-
mutually exclusive mechanisms. These mechanisms might differ across tissues due to the variable 
amount of lamin A (and progerin) produced, depending on tissue stiffness (63, 64). 
Progerin elicits its detrimental effects in a dose-dependent manner. Different progerin-causing 
LMNA point mutations lead to a wide spectrum of disease severity, ranging from neonatal to late-onset 
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premature aging, which correlates with the expression level of progerin (65, 66). Thus, antisense 
oligonucleotide treatment, which reduced the amount of progerin, ameliorated the vascular or aging 
phenotype in two different LmnaG609G/G609G mouse models (59, 61). 
The farnesyl group, which anchors progerin in the inner nuclear membrane, is believed to 
account for at least part of its toxic effect. This hypothesis was initially supported by findings on 
ZMPSTE24 deficiency in humans and mice, which results in the accumulation of farnesylated prelamin 
A and causes various HGPS-like phenotypes (43, 47, 48, 62). The progeroid phenotype is milder in 
patients that carry both a heterozygous LMNA mutation and a homozygous loss-of-function ZMPSTE24 
mutation, possibly due to a reduced amount of farnesylated prelamin A (67). Likewise, Zmpste24-/- 
mice with Lmna haplodeficiency do not present any evident aging phenotype (68). The importance of 
farnesylation in the pathogenesis of HGPS was corroborated by the generation of LmnacsmHG/csmHG and 
LmnanPLAO/nPLAO mouse models expressing nonfarnesylated progerin and prelamin A, respectively, 
which did not exhibit a progeroid phenotype (69, 70). Furthermore, treatment with farnesyl transferase 
inhibitors (FTIs) reverted the nuclear defects in progerin-expressing cells (56, 71), and prolonged the 
lifespan of Zmpste24-/-and LmnaHG/+ mice (57, 72). FTIs also prevented CVD in progeroid G608G 
BAC transgenic mice (73). 
It was subsequently demonstrated that prelamin A and progerin can undergo alternative 
prenylation by geranylgeranyltransferase upon farnesyltransferase inhibition (74). Thus, inhibition of 
both farnesylation and geranylgeranylation with a combination of statins and aminobisphosphonates 
was found to ameliorate the progeriod phenotype and extend survival in Zmpste24-/- mice (74). Based 
on all the above findings, a clinical trial with HGPS patients was conducted targeting farnesylation with 
an FTI (lonafarnib) alone or in combination with a statin (pravastatin) and a bisphosphonate 
(zoledronate) (75-77). Monotherapy with lonafarnib improved vascular stiffness, bone structure, and 
audiological status in some patients, and was estimated to extend survival by 1.6 years (75, 76). Triple-
drug therapy with lonafarnib, pravastatin and zoledronate had an additional beneficial effect on bone 
mineral density, but no cardiovascular improvement was detected when compared with lonafarnib 
monotherapy (77). 
Prenylation (farnesylation and geranylgeranylation) is not the only detrimental effect of 
progerin, since the aforementioned combination treatment provided some therapeutic benefits but not 
a cure for HGPS. Supported by the observation that unfarnesylated progerin forms aggregates at the 
nuclear membrane, akin to the farnesylated form, Kalinowski et al. recently suggested that increased 
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electrostatic interactions and aggregation are also responsible for progerin association with the nuclear 
inner membrane (78). In addition, Qin et al. showed that progerin has a less heterogeneous and a more 
compact tail compared with normal lamin A, and this may affect its interaction with DNA and other 
proteins (79). Accumulating evidence shows that progerin may also elicit toxic effects through altered 
protein structure due to the deletion of 50 amino acids at the C terminus. Abnormal interactions of 
progerin with other nuclear components result in changes in nuclear shape (so-called nuclear blebbing), 
increased thickness and stiffness of the lamina, heterochromatin mislocalization, and alterations in 
nuclear pore complexes (80, 81). Lee et al. showed that progerin exhibits strong binding affinity for 
lamin A/C and this interaction induced nuclear abnormalities (82). Importantly, pharmacological 
therapy to disrupt the progerin-lamin A/C binding reduced nuclear aberrations and prevented cell 
senescence in vitro, and also ameliorated progeroid features and extended lifespan in LmnaG609G/G609G 
mice (82). 
A recent study by Ibrahim et al. revealed that methylation of progerin by ICMT might also play 
a role in premature aging syndromes (83). They showed that hypomorphic Zmpste24-/-Icmthm/hm mice 
with 70-90% lower expression and activity of ICMT present improvement in body weight, grip strength 
and bone structure, and exhibit extended survival when compared with Zmpste24-/-Icmt+/+ littermates. 
This diminished activity of ICMT leads to mislocalization of prelamin A in the nucleus and activates 
AKT-mammalian target of rapamycin (mTOR) signaling, which in turn delays cell senescence. 
However, these findings are not completely in accord with the results of Cao et al. and Graziotto et al., 
who showed that treatment with the mTOR inhibitor rapamycin activates autophagic clearance of 
progerin and reduces nuclear abnormalities (84, 85). These results clearly show that ICMT and mTOR 
are implicated in premature aging, but the precise mechanism and relationship between them awaits 
further investigation. 
 
I.6. Mechanisms underlying CVD in progeria 
I.6.1. VSMC loss 
 Progressive VSMC loss was reported both in HGPS patients (20-22) and in various progeria 
mouse models (58, 59, 61), indicating its importance in the pathogenesis of the premature vascular 
disease. Depletion of VSMCs in the media has also been described in physiological aging (86), 
although not as severe as is seen in HGPS.  
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VSMCs in the blood vessels are subjected to high mechanical stress related to the blood flow. 
In normal conditions, cells respond to increased shear stress by increasing the expression of A-type 
lamins and changing their distribution within the nucleus (63, 87, 88). This response to physical stress 
is perturbed in progerin-expressing cells (81, 89) and may lead to cell damage and death. This premise 
is supported by the work of Verstraeten et al., showing reduced viability and increased apoptosis of 
HGPS fibroblasts under repetitive mechanical strain (90). One possible explanation for the progerin-
induced increase in mechanosensitivity relates to changes in the expression of proteins controlling 
cytoskeleton organization, mechanotransduction and extracellular matrix production (91, 92). Song et 
al. showed that the ascending aorta of G608G BAC transgenic mice exhibits reduced expression of 
vimentin (91), a cytoskeletal protein attached to the nucleus, endoplasmic reticulum, and mitochondria 
that is important for maintaining cellular integrity (93). This correlation between downregulation of 
mechanotransduction proteins and high shear stress in progerin-expressing VSMCs might partially 
explain their loss in HGPS. 
To elucidate how progerin leads to VSMC death, various groups established an in vitro model 
of human smooth muscle cells (SMCs) differentiated from HGPS induced pluripotent stem cells 
(iPSCs). Liu et al. showed that iPSC-derived progerin-expressing SMCs exhibit premature senescence 
associated with vascular aging, and they identified DNA-dependent protein kinase catalytic subunit 
(DNA-PKcs) as a binding partner of progerin (94). DNA-PKcs, which is a catalytic subunit of a nuclear 
DNA-PK, participates in the non-homologous end joining (NHEJ) pathway of DNA repair. Recently, 
Kinoshita et al. analyzed the interactome of lamin A mutant forms and they found that progerin, unlike 
wild-type lamin A, cannot bind to proteins related to DNA damage response, including DNA-PK 
holoenzyme (95). They also reported that progerin expression in VSMCs, but not in endothelial cells 
(ECs), induces DNA-PK activation and growth arrest, leading to cell senescence. Given that the results 
of Liu et al. and Kintoshita et al. are somewhat contradictory, the interaction between progerin and 
DNA-PK and its subunits should be further defined. 
Zhang et al. found that HGPS iPSC-derived SMCs exhibit severe proliferative defects triggered 
by a caspase-independent mechanism (96). They also reported that progerin expression in SMCs is 
associated with inhibition of poly(ADP-ribose) polymerase 1, an important regulator of DNA repair, 
and induces the activation of the error-prone NHEJ response. The subsequent prolonged mitosis results 
in mitotic catastrophe, leading to SMC death. Similar to progerin, prelamin A induces DNA damage 
and increases DNA damage response in aged VSMCs (97, 98). This response might be the consequence 
of impaired recruitment of 53 binding protein-1 (53BP1) to the sites of DNA damage due to a defective 
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import of 53BP1 to the nucleus, related to mislocalization of nucleoporin 153 (99). Defective DNA 
damage repair has been also described in non-vascular HGPS cells and in progeria mouse models (100-
102). All of the above findings confirm the contribution of DNA damage response to progerin-driven 
VSMC death. Interestingly, DNA damage plays an important role in normal aging (103). 
 
I.6.2. Vascular calcification 
HGPS patients exhibit excessive aortic and valvular calcification (20, 31, 32, 104), which is 
also a hallmark of physiological aging (105). Likewise, vascular calcification is observed in progeroid 
transgenic G608G BAC and knock-in LmnaG609G/+ mice (58, 60). Villa-Bellosta et al. (60) found 
abnormally high expression of the osteogenic markers bone morphogenetic protein 2 (Bmp2) and Run-
related transcription factor-2 (Runx2) in calcified aortas from LmnaG609G/+ mice, without alterations in 
the anti-calcification agents matrix Gla-protein and fetuin A. Moreover, LmnaG609G/+-derived primary 
VSMCs showed a reduced capacity to inhibit calcium deposition in vitro, which was associated with a 
decreased amount of extracellular inorganic pyrophosphate (ePPi), the major endogenous inhibitor of 
vascular calcification. The diminished level of ePPi was related to an impairment in ePPi synthesis due 
to decreased ATP production (the main substrate for ePPi synthesis) and an upregulation of tissue-
nonspecific alkaline phosphatase (the main enzyme involved in PPi hydrolysis) and ectonucleoside 
triphosphatase diphosphohydrolase 1 (the enzyme that hydrolyzes ATP to release Pi). Accordingly, 
plasma concentrations of ePPi and ATP were found to be lower in LmnaG609G/+ mice than in Lmna+/+ 
littermates. Moreover, injection of exogenous PPi prevented vascular calcification in LmnaG609G/G609G 
mice. 
The diminished capacity of progerin-expressing VSMCs to prevent calcification might be 
related to a switch from a contractile to an osteochondrocytic phenotype. This notion is supported by 
the work of Liu et al., who showed that prelamin A accumulation in VSMCs interferes with DNA 
damage repair leading to osteogenic differentiation (98). These findings are of special interest because, 
similar to progerin, prelamin A accumulates with age in medial VSMCs and atherosclerotic lesions, 
and has been proposed as a novel biomarker of VSMC aging (97). Prelamin A activates DNA damage-
related ataxia telangiectasia mutated /ataxia telangiectasia and Rad3-related signaling, and induces 
senescence-associated secretory phenotype in VSMCs (98). Prelamin A-expressing senescent VSMCs 
release pro-calcification factors, such as BMP2, which may trigger calcification both locally and at 
remote sites.  
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A recent study also demonstrated that VSMCs cultured in calcifying medium show higher 
expression of lamin A and prelamin A, accompanied by upregulated gene expression of relevant 
regulators of calcification, such as Runx2, osteocalcin and osteopontin, and increased calcium 
deposition (106). Remarkably, human mesenchymal stems cells expressing progerin also show elevated 
levels of osteopontin and exhibit enhanced osteogenic differentiation (107). In summary, lamin A and 
its mutant or unprocessed forms participate in osteoblastic differentiation and vascular calcification, 
indicating a further need to examine the role of progerin and prelamin A in premature and physiological 
aging. 
 
I.6.3. Endothelial dysfunction 
EC dysfunction is an essential event in atherosclerosis development, which is the life-
threatening component of HGPS. It has been well established that aortic regions subjected to turbulent 
blood flow and high shear stress, such as the ascending aorta, are more susceptible to atheroma plaque 
formation (108, 109). ECs can sense and respond to different types of blood flow. Song et al. observed 
that ECs in the ascending aorta of G608G BAC mice form an intact monolayer in the zones with an 
almost complete loss of VSMCs (91). Moreover, these ECs showed a greater than 8-fold increase in 
vimentin levels compared with ECs in zones with preserved VSMCs. An elevated level of vimentin in 
progerin-expressing ECs might augment their resistance to increased shear stress, thus explaining the 
presence of well-preserved endothelium in HGPS vessels (20).  
A recent study showed that accumulation of prelamin A in ECs, through blocking lamin A 
maturation, induces cell senescence and promotes intercellular adhesion molecule 1-dependent 
monocyte adhesion to ECs (110). Since monocyte adhesion to ECs and extravasation is an important 
step in the initiation of the atheroma plaque formation, further studies are needed to unravel the 
relationship between progerin and prelamin A expression in ECs and atheroma build-up. 
 
I.6.4. Cardiac electrical alterations 
Previous studies in HGPS patients revealed repolarization abnormalities, such as ST segment 
depression/elevation and negative and biphasic T waves, which were especially evident at advanced 
stages of the disease (17, 30). Progeriod Zmpste24-/- mice show similar alterations manifesting as T-
wave flattening (30). Although progerin-expressing LmnaG609G/G609G and prelamin A-expressing 
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Zmpste24-/- mice develop severe bradycardia as they age, HGPS patients present cardiac rhythm that 
remains within the normal range; yet, the heart rate seemed to be slower in older patients (30, 59). 
Moreover, 18-20-week-old Zmpste24-/- animals showed prolonged PQ interval and QRS complex, 
indicating defective cardiac conduction (30). These alterations were accompanied by mislocalization 
of the gap junction protein connexin 43, which was also evident in heart tissue from HGPS patients 
(30). Intercellular connectivity defects might therefore underlie cardiac electrical defects in progeria. 
Taken together, these findings suggest that cardiac alterations in HGPS patients and progeroid mice are 
a characteristic of progeria that could increase the risk of arrhythmias and lead to premature death. 
 
I.7. Endoplasmic reticulum (ER) stress and the unfolded protein response (UPR) 
Aging has been linked to the capacity of an organism to cope with stress stimuli (111, 112). 
Organisms have a wide variety of stress response mechanisms that can act at the cellular or organelle-
specific level to restore homeostasis, including heat shock response, autophagy, mitochondrial and ER 
stress responses, remodeled proteasome, and the DNA damage response (112). These stress responses 
involve recognition of the damage, transmission of the stress signal to the nucleus, production of stress-
related proteins and their translocation to the site of damage. Impaired responses to stress are believed 
to contribute to age-related tissue damage, but compromised stress response can also accelerate aging. 
Alterations in the ER stress response have been linked to some age-associated diseases such as 
diabetes, heart disease and neurodegenerative disorders (113-115). In response to certain stress stimuli, 
such as free cholesterol, oxidized lipids, high glucose, mitochondrial dysfunction and calcium 
imbalance, unfolded proteins accumulate within the ER, leading to ER stress (116, 117). In an attempt 
to reestablish homeostasis, ER stress triggers several adaptive mechanisms, which together are known 
as the UPR (116, 118). UPR activation leads to diminished misfolded or unfolded protein load by 
reducing the influx of proteins into the ER, synthesizing proteins responsible for folding and quality 
control in the ER, and increasing the ER membrane size (119-122). However, under persistent stress 
conditions, UPR fails to restore homeostasis and triggers programmed cell death (123). 
Three classes of ER stress sensors are known to mediate UPR activation: inositol-requiring 
enzyme 1 (IRE1), protein kinase RNA-like ER kinase (PERK), and activating transcription factor 6 
(ATF6) (118) (Fig. 2). These transmembrane receptors are maintained in an inactive form through 
binding to the ER chaperone 78 kDa glucose-regulated protein (GRP78), also known as 
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immunoglobulin heavy chain-binding protein. In the presence of high levels of misfolded or unfolded 
proteins, GRP78 dissociates from IRE-1, PERK and ATF6, enabling their activation (124). 
During the early stages of the UPR, protein synthesis is inhibited by blocking translation in a 
process mediated by the PERK-dependent phosphorylation of eukaryotic translation initiator factor 2α 
(eIF2α) (125). Moreover, regulated IRE1-dependent decay leads to degradation of specific mRNAs 
that code for ER-located proteins (126-128). ER stress also stimulates autophagy though the IRE1-JUN 
N-terminal kinase pathway, in order to eliminate damaged ER and aberrant protein aggregates (129). 
Generally, these first-line responses aim to reduce protein influx into the ER and facilitate adaptive and 
repair mechanisms that restore homeostasis. 
During the middle stages of the UPR, the transcription factors ATF6 fragment (ATF6f), spliced 
X box-binding protein 1 (XBP1s) and ATF4 are activated to restore ER function and promote survival. 
Under ER stress, ATF6 dissociates from GRP78 and translocates to the Golgi apparatus, where it is 
cleaved (130, 131). The resulting cytosolic fragment ATF6f enters the nucleus and stimulates 
transcription of the ER-associated protein degradation (ERAD) constituents and XBP1 (132, 133). 
Dimerization and autotransphosphorylation of IRE1 upon ER stress results in the activation of 
its cytosolic RNase domain (134). Active IRE1 excises 26 nucleotides from the mRNA coding for 
XBP1, leading to a shift in the reading frame and the production of an active and stable transcription 
factor called XBP1s (s for “spliced”) (133, 135, 136). Subsequently, XBP1s enters the nucleus and 
activates the transcription of genes that encode proteins involved in ERAD and protein folding (137, 
138). XBP1s also regulates phospholipid synthesis, leading to the ER membrane expansion upon ER 
stress (139). By contrast, XBP1, which is the protein product of unspliced XBP1 mRNA, is unstable 
and inhibits UPR target gene transcription (135). 
Although PERK activation leads to the attenuation of translation, it upregulates the expression 
of some proteins, including ATF4 and GRP78 (140, 141). ATF4 regulates genes responsible for amino 
acid metabolism, redox balance, protein folding and autophagy (122, 142). Moreover, it also promotes 
eIF2α dephosphorylation and translation recovery by increasing the expression of growth arrest and 
DNA damage-inducible gene 34 (143). 
Although UPR is a pro-survival mechanism, it can lead to cell death in situations of acute or 
chronic ER stress. The central factor orchestrating the ER stress-related apoptosis is DNA damage-
inducible transcript 3 protein (DDIT3), also called growth arrest and DNA damage-inducible protein 
or CCAAT/enhancer-binding protein homologous protein (144). Under normal conditions, the amount 
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of DDIT3 in the cell is low; however, the protein level of DDIT3 increases via IRE1-, PERK- and 
ATF6- pathways upon ER stress activation (although ATF4 plays the main role in the activation of 
DDIT3 gene expression). In turn, DDIT3 upregulates tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL) receptors, leading to activation of the extrinsic apoptotic pathway (145). In addition to 
DDIT3, other factors mediating ER stress-related apoptosis have been proposed, including IRE1 and 
caspase 12 (122). 
 
Figure 2. A simplified scheme of endoplasmic reticulum (ER) stress and the unfolded protein response (UPR) 
activation. Three UPR-related molecules are activated upon ER stress: activating transcription factor 6 (ATF6), inositol-
requiring enzyme 1 (IRE1), and protein kinase RNA-like ER kinase (PERK). At the early stages of the UPR, protein 
translation is diminished through PERK-mediated phosphorylation of eukaryotic translation initiator factor 2α (eIF2α). 
Moreover, initiation of regulated IRE1- dependent decay (RIDD) leads to decay of some mRNAs. In parallel, autophagy 
is activated via the IRE1α–JUN N-terminal kinase (JNK) pathway. At the middle stages of the UPR, three transcription 
factors (activating transcription factor 6 cytosolic fragment (ATF6f), spliced X box-binding protein 1 (XBP1s) and 
ATF4) promote various adaptive responses in order to reestablish ER function and promote cell survival. However, 
unresolved ER stress triggers apoptosis via different pathways, with DNA damage-inducible transcript 3 protein 
(DDIT3; also known as C/EBP-homologous protein) being the key transcription factor regulating this process. Dashed 
lines indicate events promoting apoptosis. ERAD: ER-associated protein degradation. 
 
 
 27 
 
II. OBJECTIVES 
  
II. OBJECTIVES 
29 
 
Since the discovery in 2003 of the HGPS-causing mutation in the LMNA gene, much progress 
has been made in unraveling the mechanisms underlying progerin-induced premature aging and death. 
However, few studies have investigated the molecular alterations triggered by progerin accumulation 
in VSMCs, major players in atherosclerosis development (60, 94-96, 146). Moreover, the mechanisms 
through which progerin accelerates atherosclerosis remain largely undefined, in part due to the lack of 
adequate mouse models. 
Ongoing HGPS clinical trials are testing FTIs, either as monotherapy or in combination with 
bisphosphonates and statins (75-77). These strategies are clearly not curative since most HGPS 
symptoms persist in treated patients, including CVD and premature death. Further research is therefore 
needed to identify new disease mechanisms and to develop more efficient therapies to inhibit 
atherosclerosis development, the main cause of death in HGPS patients. 
The main objectives of this thesis were the following: 
1. To generate the first progeroid mouse model exhibiting progerin-induced acceleration of 
atherosclerosis that phenocopies the main vascular alterations observed in HGPS patients. 
2. To assess the relative contribution of macrophages and VSMCs to progerin-driven 
atherosclerosis. 
3. To identify the molecular mechanisms underlying progerin-induced atherosclerosis. 
4. To test new treatments to prevent cardiovascular events and extend lifespan of progeric 
mice that could be used in HGPS patients. 
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III.1. Mice 
All experimental and other scientific procedures with animals conformed to EU Directive 
2010/63EU and Recommendation 2007/526/EC, enforced in Spanish law under Real Decreto 53/2013. 
Animal protocols were approved by the local ethics committees and the Animal Protection Area of the 
Comunidad Autónoma de Madrid (PROEX76/14, PROEX78/14, PROEX167/16). 
All mice used in this study were male on the C57BL/6J genetic background. Apolipoprotein E-
deficient (Apoe-/-, The Jackson Laboratory, stock no: 002052), LmnaG609G/+ (59), LmnaLCS/+ (59), 
SM22αCre (Tagln-Cre, The Jackson Laboratory, stock no: 017491), and LysMCre (147) mice were 
purchased or kindly provided by collaborators. These lines were used to generate atherosclerosis-
susceptible mouse models with ubiquitous progerin expression (Apoe-/-LmnaG609G/G609G), VSMC-
specific progerin expression (Apoe-/-LmnaLCS/LCSSM22αCre), macrophage (myeloid)-specific progerin 
expression (Apoe-/-LmnaLCS/LCSLysMCre), and their corresponding controls expressing normal lamin 
A/C (Apoe-/-Lmna+/+) or lamin C only (Apoe-/-LmnaLCS/LCS). Moreover, to compare the atherosclerosis-
prone (Apoe-/-) and atherosclerosis-resistant (Apoe+/+) backgrounds, we bred LmnaLCS/LCSSM22αCre, 
LmnaLCS/LCS, LmnaG609G/G609G and Lmna+/+ mice. With the exception of longevity studies, animals on 
the Apoe-/- background were sacrificed at 8, 16, 21-23, 27 or 51 weeks of age (indicated in the figure 
legends). LmnaLCS/LCSSM22αCre and LmnaLCS/LCS mice were sacrificed at 38 week of age. 
 
III.2. Longevity study 
Beginning at 4 weeks of age, animals were weighed and inspected for health and survival at 
least once per week (checks were more frequent for Apoe-/-LmnaG609G/G609G mice). Diseased animals 
were examined by a specialized veterinarian blinded to genotype. Animals that met humane endpoint 
criteria were euthanized and the deaths recorded. Animals sacrificed due to hydrocephalus, 
malocclusion, inter-male aggression or other reasons unconnected to phenotype, were excluded from 
the analysis (normally at a very early stage of the study). 
 
III.3. High-fat diet (HFD) experiments 
For diet-induced atherosclerosis studies, animals were maintained for 8 weeks on a HFD (10.7% 
total fat, 0.75% cholesterol, S9167-E010, Ssniff), beginning at 8 weeks of age. Mice were sacrificed at 
16 weeks of age after an overnight fast. 
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III.4. Hematology and serum biochemical analysis 
Animals were fasted overnight for all blood analyses, which were performed by specialized 
staff from the CNIC Animal Unit. For hematology, blood samples were collected in Microvette 100 
EDTA tubes (Sarstedt) and analyzed using a PENTRA 80 hematology analyzer (Horibo). For 
biochemical analysis, blood samples were collected in plastic tubes, incubated at room temperature 
(RT) for 2-3 hours to allow clotting, and centrifuged at 2000 × g for 5 minutes. Serum was stored at -
80°C until samples from all experiments were collected. Because of volume limitations, serum samples 
were pooled from approximately 2-3 animals of the same experimental group. Specimens with overt 
hemolysis were excluded from testing. Biochemical variables were analyzed using a Dimension RxL 
Max Integrated Chemistry System (Siemens Healthineers). 
 
III.5. Blood pressure measurement 
Blood pressure and heart rate measurements were performed in conscious mice using the 
BP2000 noninvasive automated tail-cuff system (Visitech Systems). All experiments were performed 
in the morning to avoid variability related to circadian oscillations in the blood pressure (148, 149). 
Animals were trained during five consecutive days (first week) and then experimental data was 
collected during 5 consecutive days (second week). For each mouse, at least 10 measurements of blood 
pressure and heart rate were registered each day. Final measurements were preceded by 10 preliminary 
measurements to allow the animals to settle. Values that were equal to 0 (which arose from equipment 
error or animal movements) were excluded from the analysis. For each day, the median was calculated 
for the heart rate, systolic and diastolic blood pressure. The mean from 5 days was used for further 
analysis. 
 
III.6. ECG 
Mice were anesthetized with 1.5-2% isoflurane and four ECG electrodes were inserted 
subcutaneously into the limbs. ECG was recorded in the morning (to account for circadian variations) 
using the MP36R system (Biopac Systems). ECG data were analyzed using AcqKnowledge software 
by specialized staff blinded to the genotype. 
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III.7. Treatment 
Tauroursodeoxycholic acid (TUDCA, 580549, Calbiochem) was dissolved in phosphate-
buffered saline (PBS) and passed through a 0.22 µm filter. After genotyping, mice were randomized 
into treatment and control groups (an equal or similar number of animals from each litter was assigned 
to each group). TUDCA (400 mg/kg) or PBS was administered intraperitoneally 3 times a week, 
beginning at 6 weeks of age in the case of Apoe-/-LmnaG609G/G609G mice and at 8 weeks of age in the 
case of Apoe-/-LmnaLCS/LCSSM22αCre mice. Atherosclerosis experiments included PBS- or TUDCA-
treated Apoe-/-Lmna+/+ and Apoe-/-LmnaLCS/LCS control mice. 
 
III.8. Quantification of atherosclerosis burden 
Mouse aortas were fixed with 4% formaldehyde/PBS, cleaned of fatty tissue, and stained with 
0.2% Oil Red O (ORO, O0625, Sigma). The thoracic aorta or/and aortic arch was then incised 
longitudinally and pinned out flat, intimal side up, for computer-assisted planimetric analysis. Images 
were taken with a digital camera (OLYMPUS UC30) mounted on a stereo microscope (OLYMPUS 
SZX3). The percentage of lesion area (ORO-stained) was quantified using SigmaScan Pro 5 software 
(Systat Software Inc.) by an observer blinded to genotype. 
 
III.9. Histology and immunofluorescence 
For all mice on the Apoe-/- background, formaldehyde-fixed aortic arches were cleaned of fatty 
tissue, incubated in 30% sucrose in PBS overnight at 4°C, and embedded in Tissue-Tek® OCT 
compound (SAKURA, Netherlands) for cryostat sectioning. Serial 8-μm sections were stained with 
ORO, hematoxylin-eosin (H&E), and Masson’s trichrome. For immunofluorescence, sections were 
blocked and permeabilized for 1 hour at RT in PBS containing 0.3% Triton X-100 (9002-93-1, Sigma), 
5% bovine serum albumin (BSA, A7906, Sigma), and 5% normal goat serum (005-000-001, Jackson 
ImmunoResearch). Next, sections were incubated overnight at 4°C with the following antibodies: anti-
smooth muscle α-actin (Sma-Cy3, C6198, Sigma, 1:200), anti-CD68 (MCA1957, Serotec, 1:200), and 
anti-progerin/lamin A (sc-20680, Santa Cruz, 1:100) diluted in PBS containing 0.3% Triton X-100 and 
2.5% normal goat serum. Samples were incubated with corresponding secondary antibodies (Alexa 
Fluor, Invitrogen) and the nucleic acid stain Hoechst 33342 (B2261, Sigma) for 2 hours at RT, and 
mounted using Fluoromount G imaging medium (4958-02, Affymetrix eBioscience). 
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Aortic arches of LmnaLCS/LCSSM22αCre and LmnaLCS/LCS mice were fixed in 4% formaldehyde 
in PBS, cleaned of fatty tissue, dehydrated to xylene and embedded in paraffin. Thoracic aortas used 
for atherosclerosis burden quantification (from TUDCA-treatment experiments) were also embedded 
in paraffin. Serial 4-μm sections were deparaffinized, rehydrated, and stained with H&E, and Masson’s 
trichrome. For immunofluorescence, antigen retrieval was performed using 10 mM sodium citrate 
buffer (pH 6). Then, samples were blocked with PBS containing 5% BSA and 5% normal goat serum 
for 1 hour at RT. Sections were incubated for 2 hours at RT with an anti-smooth muscle α-actin 
antibody (Sma-Cy3, C6198, Sigma, 1:200) and Hoechst 33342 stain diluted in PBS with 2.5% normal 
goat serum, and mounted using Fluoromount G imaging medium. 
Mouse hearts were fixed in 4% formaldehyde in PBS, divided into two parts (apex and upper 
part containing aortic root with aortic valve), dehydrated to xylene and embedded in paraffin. Heart 
(apex) sections from 6 different levels were prepared. The aortic root was sectioned throughout the 
aortic valve. Serial 4-μm sections were deparaffinized, rehydrated, and stained with H&E, and 
Masson’s trichrome.  
ORO-, H&E- and Masson’s trichrome-stained sections were scanned with a NanoZoomer-RS 
scanner (Hamamatsu), and images were exported using NDP.view2. Immunofluorescence images were 
acquired with the Zeiss LSM 700 confocal microscope. Images were analyzed using NDP.view2 and 
ImageJ Fiji software by an observer blinded to genotype. Aortic media and adventitia thickness, 
collagen and lipid medial content, and VSMC content were analyzed in approximately 3 sections (for 
aortic arch) and/or 4 (for thoracic aorta) per animal, and the mean was used for the statistical analysis. 
Atherosclerotic plaque area, plaque collagen and VSMC content were quantified in 3 different zones 
of the aortic valve (beginning, middle, and end) per animal, and the mean was used for the statistical 
analysis. 
 
III.10. Sample collection and preparation for RNAseq 
Eight-week-old mice (Apoe-/-LmnaG609G/G609G, Apoe-/-Lmna+/+, Apoe-/-LmnaLCS/LCSSM22αCre 
and Apoe-/-LmnaLCS/LCS) were sacrificed by CO2 inhalation, and thoracic aortas were extracted, cleaned 
of fatty tissue and digested with 2 mg/ml collagenase (CLS-2, Worthington) for 10 minutes at 37°C to 
separate medial and adventitial tissue. Medial aortas from 3-4 mice of the same genotype were pooled 
and snap frozen. Samples were disrupted using TissueLyser (Qiagen), and total RNA was isolated with 
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QIAzol (Qiagen). RNA integrity was confirmed by RNA electrophoresis and with an Agilent 2100 
Bioanalyzer. 
 
III.11. RNAseq library preparation, sequencing, and generation of FastQ files 
Total RNA (500 ng) was used to generate barcoded RNAseq libraries using the TruSeq RNA 
Sample Preparation Kit v2 (Illumina). Briefly, poly A+ RNA was purified using poly-T oligo-attached 
magnetic beads through two rounds of purification, followed by fragmentation and first and second 
cDNA strand synthesis. Next, cDNA 3’ ends were adenylated and the adapters were ligated, followed 
by PCR library amplification. Finally, library size was checked using the Agilent 2100 Bioanalyzer 
DNA 1000 chip and concentration was determined in a Qubit® fluorometer (Life Technologies). 
Libraries were sequenced on a HiSeq2500 sequencer (Illumina) to generate 60-base single reads. FastQ 
files for each sample were obtained using CASAVA v1.8 (Illumina). NGS experiments were performed 
in the CNIC Genomics Unit. RNAseq data were deposited in the NCBI SRA, accession number: 
SRP099105. 
 
III.12. Differential expression analysis 
Sequencing reads were pre-processed by means of a pipeline that used FastQC (150) to assess 
read quality, and Cutadapt (151) to trim sequencing reads and eliminate Illumina adaptor sequences, 
and to discard reads that were shorter than 30 base pairs. The number of reads obtained per sample was 
in the range of 8 to 14 million. The resulting reads were mapped against the mouse transcriptome 
(GRCm38, release 76; aug2014 archive) and quantified using RSEM v1.17 (152). The percentage of 
aligned reads was in the range of 79 to 82%. Data were then processed with a differential expression 
analysis pipeline that used the Bioconductor package EdgeR (153) for normalization and differential 
expression testing. Only genes with at least 1 count per million in at least 4 samples (13,664 genes) 
were considered for statistical analysis. Three comparisons were made to identify differentially 
expressed genes in our models: 1) Apoe-/-LmnaG609G/G609G vs Apoe-/-Lmna+/+; 2) Apoe-/-
LmnaLCS/LCSSM22αCre vs Apoe-/-LmnaLCS/LCS; and 3) Apoe-/-LmnaLCS/LCS vs Apoe-/-Lmna+/+. The lists of 
genes detected as differentially expressed in the 3 comparisons were subjected to a series of 
bioinformatic analyses. The list of 240 genes shared between comparisons 1 and 2 was extracted and 
the logFC values (base-2 logarithm of fold change) for those genes were plotted against each other 
III. MATERIALS AND METHODS 
38 
 
using Microsoft Excel to check for correlation. Differential expression analysis was performed in the 
CNIC Bioinformatics Unit. Area-proportional Venn diagrams were generated using BioVenn (154) to 
visualize the overlap between data sets. 
 
III.13. Pathway analysis  
Ingenuity Pathway Analysis (IPA, Qiagen) was used for more comprehensive RNAseq data 
analysis. Briefly, core analyses were performed for the 3 comparisons to visualize pathways altered by 
progerin expression as well as by the lack of lamin A. Benjamini-Hochberg correction of the P value 
was applied to extract the most significant pathways and stacked bar charts were exported. A 
comparison analysis was performed to compare results obtained with ubiquitous and VSMC-specific 
progeroid models. Heatmaps showing canonical pathways and upstream regulators were exported. For 
more detailed information about IPA tools (Global Canonical Pathways, Upstream regulators and 
Comparative analysis), see www.ingenuity.com. 
 
III.14. RNA extraction and cDNA preparation 
Tissues were homogenized using TissueLyser (Qiagen), and total RNA was extracted with 
QIAzol reagent (Qiagen). The RNA pellet was dissolved in RNase-free water and concentration was 
measured in a NanoDrop spectrophotometer (Wilmington). RNA (2 µg) was transcribed to cDNA using 
the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems).  
 
III.15. PCR detection of lamin A and progerin  
Lamin A and progerin mRNA levels were quantified according to a protocol adapted from Yang 
et al. (155). cDNA (100 ng for medial aortas and 200 ng for other organs) was amplified by PCR using 
DNA polymerase (Biotools, Spain). PCR products were separated on a 2% agarose gel containing 
ethidium bromide. Images were taken with a Molecular Imager® Gel Doc™ XR+ System (BioRad) 
and analyzed with Image Lab™ (BioRad).  
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III.16. Quantitative real-time PCR 
qPCR reactions were prepared using Power SYBR® Green PCR Master Mix (Applied 
Biosystems). PCR reaction mixes were loaded on 384-well plates (Applied Biosystems) and run on a 
7900-FAST-384 thermal cycler (Applied Biosystems). All reactions were performed in triplicate. 
Primers used in this study are as follows: Calr (F: 5′-CCAGAAATTGACAACCCTGAA-3′, R: 5′-
CCTTAAGCCTCTGCTCCTCAT-3′), Ddit3 (F: 5′-ATATCTCATCCCCAGGAAACG-3′, R: 5′-
CTCCTGCTCCTTCTCCTTCAT-3′), Dnajb9 (F: 5′-AGAATTAATCCTGGCCTCCAA-3′, R: 5′-
GGCATCCGAGAGTGTTTCATA-3′), Hspa5 (F: 5′-GTGGGAGGAGTCATGACAAAA-3′, R: 5′-
TTCAGCTGTCACTCGGAGAAT-3′), Hsp90b1 (F: 5′-AGTGGAAGAGGACCTGGGTAA-3′, R: 5′-
AGCGAGTGCATTTTCATCAGT-3′), Pdia4 (F: 5′-TCCTGAAGGATGGAGATGATG-3′, R: 5′-
ACCTGGGCTCATACTTGGACT-3′), Gusb (F: 5′-GAGTATGGAGCAGACGCAATC-3′, R: 5′-
TCCGACCACGTATTCTTTACG-3′), and Hprt (F: 5′-AGGCCAGACTTTGTTGGATTT-3′, R: 5′-
GGCTTTGTATTTGGCTTTTCC-3′). 
 
III.17. Statistical analysis 
Experimental data are presented as mean (error bars indicate standard error of the mean (SEM)) 
for parametric data, or median with interquartile range (error bars indicate minimum and maximum) 
for non-parametric data. For small sample sizes, data were plotted as independent points (dot plots). 
Based on all experiments, distribution of a variable (lesion size, nucleus count, etc.) was assessed using 
the Kolmogorov-Smirnov and D'Agostino-Pearson normality tests. If the distribution was normal in 
most of the experiments, a two-tailed t-test was used, except for the validation of RNAseq data by 
qPCR and VSMC content quantification after TUDCA treatment where a one-tailed t-test was used. If 
the distribution of a variable was skewed, the two-tailed Mann-Whitney test was used, except for the 
adventitia-to-media ratio quantification after TUDCA treatment where a one-tailed Mann-Whitney test 
was used. To compare multiple groups, one-way ANOVA with Tukey´s post hoc test was used for both 
parametric and non-parametric data because this approach is resistant to normality violations with 
similar sized groups. A log-rank (Mantel-Cox) test was used for Kaplan-Meier survival curves. 
Differences were considered significant at P < 0.05. Statistical analysis was performed with GraphPad 
Prism 5. 
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IV.1. Ubiquitous progerin expression aggravates atherosclerosis in HFD-fed Apoe-/- mice 
Among the available HGPS-like mouse models, LmnaG609G/G609G knock-in mice ubiquitously 
expressing progerin recapitulate most of the clinical manifestations of HGPS, including growth 
impairment, bone abnormalities, lipodystrophy, vascular calcification, and reduced survival (average 
lifespan: ≈15 weeks) (59, 60). However, we did not observe atherosclerosis in aortas of LmnaG609G/G609G 
mice even when 8-week-old animals were challenged with HFD for 8 weeks (Fig. 3). This finding is 
consistent with the observation that, unlike humans, mice are extremely resistant to atherosclerosis 
development, due in part to differences in cholesterol and lipoprotein metabolism (156).  
 
Figure 3. LmnaG609G/G609G mice do not show any signs of atherosclerosis development. LmnaG609G/G609G and Lmna+/+ 
mice were fed high-fat diet for 8 weeks starting at 8 weeks of age. Mice were sacrificed at 16 weeks (close to their maximum 
survival) and aortas were stained with Oil Red O to visualize lipid-rich atheroma plaques. No red staining was observed 
indicating absence of atherosclerosis. 
 
To circumvent this limitation, we generated an atherosclerosis-prone mouse model of HGPS by 
crossing LmnaG609G/+ mice with Apoe-/- mice, a widely-used model of atherosclerosis (156). As 
expected, Apoe-/-LmnaG609G/G609G mice showed decreased body weight and a shortened life span 
(median survival: 18.5 weeks) as compared with Apoe-/-Lmna+/+ littermates with normal Lmna gene 
expression (median survival: 117.6 weeks) (Fig. 4). Notably, the Apoe-/-LmnaG609G/G609G phenotype, 
including survival and body weight curves, was similar to that of LmnaG609G/G609G mice (59). 
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Figure 4. Ubiquitous progerin expression in Apoe
-/-
Lmna
G609G/G609G
 mice impairs postnatal growth and reduces 
lifespan. (A) Postnatal body weight curves for Apoe
-/-
Lmna
+/+
 mice (n=7) and Apoe
-/-
Lmna
G609G/G609G
 mice (n=14). (B) 
Kaplan-Meier survival curves. Median survival = 18.5 weeks for Apoe
-/-
Lmna
G609G/G609G 
mice (n=14) and 117.6 weeks for 
Apoe
-/-
Lmna
+/+
 mice (n=7); P<0.001. (C) Representative photograph of 16-week-old males. Data are presented as mean ± 
SEM in A. Statistical analysis was performed by log-rank test in B. 
 
To study the influence of progerin on atherosclerosis development, 8-week-old mice were 
challenged for 8 weeks with HFD. Pre-HFD fasting serum lipid levels, including total cholesterol, free 
cholesterol, LDL and HDL, were indistinguishable between experimental groups (Fig. 5A). However, 
post-HFD levels were significantly lower in Apoe-/-LmnaG609G/G609G mice than in Apoe-/-Lmna+/+ 
controls (Fig. 5B), probably due to a reduced food intake related to premature aging and associated 
disease progression in progeric mice. Nevertheless, despite the lower serum lipid levels, atherosclerosis 
burden assessed by ORO staining was 1.8-fold higher in the aortic arch and 3.1-fold higher in the 
thoracic aorta of HFD-fed Apoe-/-LmnaG609G/G609G mice (Fig. 5C). Both groups had focal aortic lesions, 
but the aortic surface of progeroid Apoe-/-LmnaG609G/G609G mice was covered with lipid deposits, which 
were not seen in control Apoe-/-Lmna+/+ mice (Fig. 5C). 
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Figure 5. Ubiquitous progerin expression in Apoe
-/-
Lmna
G609G/G609G
 mice accelerates atherosclerosis upon high-fat 
diet (HFD). Mice were fed HFD for 8 weeks starting at 8 weeks of age. (A) Fasting serum pre-HFD levels of total 
cholesterol, free cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) in 8-week-old Apoe-/-
LmnaG609G/G609G mice (n=5) and Apoe-/-Lmna+/+ mice (n=7). (B) Fasting serum post-HFD levels of total cholesterol, free 
cholesterol, LDL, and HDL in 16-week-old Apoe-/-LmnaG609G/G609G mice (n=6) and Apoe-/-Lmna+/+ mice (n=8). (C) 
Representative aortic arches (top) and thoracic aortas (middle and bottom) stained with Oil Red O; graphs show 
quantification of atherosclerosis burden in Apoe
-/-
Lmna
G609G/G609G
 mice (n=6 aortic arches; n=12 thoracic aortas) and Apoe
-
/-
Lmna
+/+
 mice (n=9 aortic arches; n=13 thoracic aortas). Data are shown as mean ± SEM in A and B, and as median with 
interquartile range and minima and maxima in C. Statistical differences were analyzed by two-tailed t-test in A and B and 
by two-tailed Mann-Whitney test in C. *P<0.05, **P<0.01, ***P<0.001. 
 
Histology revealed that this abnormality was due to excessive lipid accumulation in the aortic 
tunica media in atheroma-free zones of Apoe-/-LmnaG609G/G609G aorta (Fig. 6A, B). These lipid deposits 
typically corresponded to the medial regions, with an almost complete loss of VSMCs (Fig. 6A). As in 
human HGPS arteries, VSMC depletion in Apoe-/-LmnaG609G/G609G mice was accompanied by increased 
collagen content in the media and abnormal elastin structure (Fig. 6A, B). Importantly, Apoe-/-
LmnaG609G/G609G mice developed adventitial thickening and inflammation (Fig. 6A, B), a relevant 
feature of HGPS. Some of the pathologies described above have been observed in other progeroid 
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mouse models, such as VSMC depletion in knock-in LmnaG609G/G609G and transgenic G608G BAC mice 
(58, 59), but not as early and as severe as in the model described here (Fig. 6C). 
 
Figure 6. Ubiquitous progerin expression in Apoe
-/-
Lmna
G609G/G609G
 mice produces severe vascular pathology, 
including lipid retention in the media, vascular smooth muscle cell (VSMC) loss, adventitial thickening, and 
increased collagen content upon high-fat diet (HFD). Mice were fed HFD for 8 weeks starting at 8 weeks of age. (A) 
Representative staining of aorta sections with Oil Red O (ORO), hematoxylin & eosin (H&E), and Masson’s Trichrome. 
(B) Graphs show quantification of lipid content in atheroma-free zones of the media (as % of ORO-positive area), adventitia-
to-media thickness ratio, and collagen content in the media (% of blue staining); n=6-8. Scale bar, 200 µm. (C) 
Representative immunofluorescence images of aortas stained with anti-smooth muscle actin (Sma) antibody (red) and 
Hoechst3442 (blue); graphs show quantification of VSMC content in the media as either % of Sma-positive area (top) or 
nucleus count (bottom); n=6-8. Scale bar, 50 µm. Box and whisker plots in B show medians, interquartile range, and minima 
and maxima; data in C are mean ± SEM. Statistical analysis was performed by two-tailed Mann-Whitney test in B, and 
two-tailed t-test in C. **P<0.01, ***P<0.001. m: media, a: adventitia. 
 
Apoe-/-LmnaG609G/G609G mice also showed significant hematological alterations in leukocyte 
subpopulations, including lower pre- and post-HFD lymphocyte and monocyte counts (Fig. 7 and 8). 
Since hematological analysis is based on the size and granularity of the cell, some of these 
measurements may be compromised because progerin affects nuclear shape. These findings should 
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therefore be confirmed by flow cytometry using specific cell surface marker antibodies to precisely 
define changes in circulating leukocyte subpopulations of Apoe-/-LmnaG609G/G609G mice. 
Although HGPS patients have increased platelet count (17), we did not find significantly higher 
amount of platelets in the blood of Apoe-/-LmnaG609G/G609G mice as compared with Apoe-/-Lmna+/+ 
controls. This progerin-driven alteration could be masked by the Apoe deficiency, because 
atherosclerosis-resistant LmnaG609G/G609G mice with an intact Apoe gene have a higher platelet count 
than Lmna+/+ littermates (data not shown). 
 
Figure 7. Apoe-/-LmnaG609G/G609G mice have lower leukocyte, lymphocyte and monocyte counts pre-high fat diet (HFD). 
Pre-HFD (fasting) hematology results for 8-week-old Apoe-/-LmnaG609G/G609G mice (n=18) and Apoe-/-Lmna+/+ mice (n=18). 
Data are shown as median with interquartile range and minima and maxima. Statistical differences were analyzed by two-
tailed Mann-Whitney test. ***P<0.001. 
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Figure 8. Apoe-/-LmnaG609G/G609G mice show higher neutrophil and lower leukocyte, lymphocyte, monocyte, and 
eosinophil counts post-high fat diet (HFD). Post-HFD (fasting) hematology results for 16-week-old Apoe-/-
LmnaG609G/G609G mice (n=17) and Apoe-/-Lmna+/+ mice (n=17). Data are shown as median with interquartile range and 
minima and maxima. Statistical differences were analyzed by two-tailed Mann-Whitney test. **P<0.01, ***P<0.001. 
 
In this study, we have generated the first mouse model of progerin-induced acceleration of 
atherosclerosis, a pathological process that leads to myocardial infarction- or stroke-related death in 
most children with HGPS. As our Apoe-/-LmnaG609G/G609G mice faithfully recapitulate most of the 
aspects of the human disease, they are a valuable tool to investigate the molecular and cellular 
mechanisms underlying premature CVD and death in HGPS. 
 
IV.2. VSMC-specific progerin expression in HFD-fed Apoe-/- mice aggravates atherosclerosis 
and shortens lifespan 
Atherosclerosis is a complex process involving many cell types, including VSMCs and 
macrophages (157). Immunohistopathological characterization of atherosclerotic plaques in HGPS 
patients suggests that both cell types contribute to progerin-driven atherogenesis (20). Since Apoe-/-
LmnaG609G/G609G mice showed medial VSMC depletion and decreased numbers of circulating 
monocytes (which give rise to macrophages in atheromata), we generated mice with specific progerin 
expression in VSMCs or macrophages to study the relative contribution of these cell types in progeria. 
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To this end, we used knock-in LmnaLCS/LCS (LaminC-STOP) mice expressing only lamin C (59). 
The LmnaLCS allele consists of a modified Lmna gene in which a neomycin resistance gene flanked 
with two loxP sequences was introduced after exon 10 to abolish lamin A production (Fig. 9). 
Additionally, an HGPS-equivalent point mutation (c.1827C>T; p.G609G) was inserted in exon 11. 
Excision of the neomycin resistance cassette in the presence of Cre recombinase enables progerin 
production (as well as lamin C and some residual lamin A). LmnaLCS/LCS mice expressing lamin C and 
lacking lamin A are apparently normal, but are slightly heavier and longer-lived than wild-type 
controls, and show decreased energy metabolism (158). 
 
Figure 9. Schematic representation of LmnaLCS allele before and after Cre-mediated recombination. The LmnaLCS 
allele carries an HGPS-causing mutation (p.G609G, indicated with an asterisk) in exon 11. However, the only product of 
the LmnaLCS allele is lamin C due to the insertion of a neomycin resistance gene after exon 10 which disables production of 
lamin A. In the presence of Cre recombinase, the neomycin resistance cassette, which is flanked with loxP sequences, is 
excised and three proteins are produced via alternative splicing: lamin C, progerin and lamin A. 
 
We first performed pilot studies to assess whether the absence of lamin A may aggravate 
atherosclerosis. To do this, we generated Apoe-/-LmnaLCS/LCS mice and analyzed atheroma plaque 
formation in 16-week-old mice challenged for 8 weeks with HFD (beginning at 8 weeks of age). No 
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significant differences in atherosclerosis burden, serum lipid levels, and hematological parameters were 
found between control Apoe-/-Lmna+/+ and Apoe-/-LmnaLCS/LCS mice (Fig. 10). 
 
 
Figure 10. Fat-fed Apoe-/-LmnaLCS/LCS mice expressing only lamin C do not show more atherosclerosis than Apoe-/-
Lmna+/+ control mice expressing wild-type lamin A/C. Mice were fed high-fat diet (HFD) for 8 weeks starting at 8 weeks 
of age. (A) Representative examples of aortas stained with Oil Red O and quantification of atherosclerosis burden in Apoe-
/-LmnaLCS/LCS mice (n=8 aortic arches, n=11 thoracic aortas) and Apoe-/-Lmna+/+ mice (n=7 aortic arches, n=11 thoracic 
aortas). (B) Post-HFD fasting serum levels of total cholesterol, free cholesterol, low-density lipoprotein (LDL), and high-
density lipoprotein (HDL) in Apoe-/-LmnaLCS/LCS (n=6) and Apoe-/-Lmna+/+ (n=7) mice. (C) Post-HFD (fasting) hematology 
results for 16-week-old Apoe-/-LmnaLCS/LCS mice (n=11) and Apoe-/-Lmna+/+ mice (n=11). Data are shown as median with 
interquartile range and minima and maxima in A and C and as mean ± SEM in B. Statistical differences were analyzed by 
two-tailed Mann-Whitney test in A and C and by two-tailed t-test in B. 
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The above result allowed Apoe-/-LmnaLCS/LCS mice to serve as controls for the cell-type-specific 
models Apoe-/-LmnaLCS/LCSLysMCre (macrophage-specific) and Apoe-/-LmnaLCS/LCSSM22Cre (VSMC-
specific). Progerin expression was verified by immunofluorescence in atheroma-containing aorta and 
by PCR in other organs. These studies confirmed that control Apoe-/-LmnaLCS/LCS mice did not express 
progerin in any organ tested (Fig. 11 and 12). By contrast, Apoe-/-LmnaLCS/LCSSM22Cre mice 
abundantly expressed progerin in medial VSMCs and to a lesser extent in the adventitia (Fig. 12), as 
well as in heart (Fig. 11). Progerin expression in Apoe-/-LmnaLCS/LCSLysMCre mice was detected in 
intimal macrophages (Fig. 12), but was either absent or negligible in other organs (Fig. 11). 
 
Figure 11. Progerin expression in different organs of progeroid and control mice. Representative images of PCR 
products showing lamin A and progerin mRNA expression in liver, kidney, spleen, and heart of 8-week-old mice of the 
indicated genotypes. Lamin A but not progerin was expressed in all organs from Apoe
-/-
Lmna
+/+ 
mice, and progerin was 
detected in all organs from Apoe
-/-
Lmna
G609G/G609G
 mice (which also expressed low levels of lamin A). Lamin A and progerin 
were undetectable or negligible in all organs of Apoe
-/-
Lmna
LCS/LCS
, Apoe
-/-
Lmna
LCS/LCS
SM22αCre, and Apoe
-/-
Lmna
LCS/LCS
LysMCre mice, with the exception of Apoe
-/-
Lmna
LCS/LCS
SM22αCre heart, which expressed both progerin and 
lamin A. Arbp was used as an endogenous control. 
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Figure 12. Progerin is expressed specifically in vascular smooth muscle cells (VSMCs) of Apoe-/-
LmnaLCS/LCSSM22αCre aorta and in macrophages of Apoe-/-LmnaLCS/LCSLysMCre aorta. Representative images of 
atheroma-containing aortas from 16-week-old mice fed a high-fat diet for 2 months starting at 8 weeks of age. Progerin was 
visualized in white, macrophages were detected with anti-CD68 antibody (green), and VSMCs with anti-Sma antibody 
(red). Nuclei were stained with Hoechst3442 (blue). Scale bar, 50µm. Amplified images show VSMC-rich media and a 
macrophage-rich atherosclerotic plaque. 
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Apoe-/-LmnaLCS/LCSLysMCre mice with macrophage-specific progerin expression showed no 
significant differences in body weight, longevity and organ size relative to controls (Fig. 13 and 14). 
Apoe-/-LmnaLCS/LCSSM22Cre mice with VSMC-specific progerin expression appeared normal early in 
life, but stopped gaining weight after approximately 20 weeks of age and died at a median age of 34.3 
weeks (Fig. 13 and 14). 
 
Figure 13. Vascular smooth muscle cell (VSMC)-specific progerin expression in Apoe
-/-
Lmna
LCS/LCS
SM22αCre mice 
reduces lifespan. (A) Postnatal body weight curves for Apoe
-/-
Lmna
LCS/LCS
 mice (n=9), Apoe
-/-
Lmna
LCS/LCS
SM22αCre mice 
(n=12), and Apoe
-/-
Lmna
LCS/LCS 
LysMCre mice (n=6). The weight curve for Apoe
-/-
Lmna
LCS/LCS
SM22αCre mice is shown up 
to the time when approximately 90% of the animals were dead. Data are presented as mean ± SEM. (B) Kaplan-Meier 
survival curves. Median survival = 34.3 weeks for Apoe
-/-
Lmna
LCS/LCS
SM22αCre mice (n=17), 106.3 weeks for Apoe
-/-
Lmna
LCS/LCS
 mice (n=9), and 116.3 weeks for Apoe
-/-
Lmna
LCS/LCS
LysMCre mice (n=6). P<0.0001 for Apoe
-/-
Lmna
LCS/LCS
SM22αCre mice vs Apoe
-/-
Lmna
LCS/LCS 
controls. Statistical analysis was performed by log-rank test. (C) 
Representative photograph of 16-week-old males. 
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Figure 14. Apoe
-/-
Lmna
LCS/LCS
SM22αCre and Apoe
-/-
Lmna
LCS/LCS 
LysMCre mice, unlike Apoe-/-LmnaG609G/G609G, show 
normal organ size. Representative images of liver, kidney, spleen, and heart of 16-week-old mice of the indicated 
genotypes. Scale bar 1 cm. 
 
We next studied atherosclerosis development in the cell type-specific models following the 
same protocol as that used for the ubiquitous progerin-expressing Apoe-/-LmnaG609G/G609G mice. The 
three experimental groups showed no inter-group differences in fasting serum lipid levels or 
hematological parameters, either pre- or post-HFD (Fig. 15 and 16). 
 
Figure 15. Apoe-/-LmnaLCS/LCSSM22αCre and Apoe-/-LmnaLCS/LCSLysMCre mice have normal serum cholesterol levels. 
Mice were fed high-fat diet (HFD) for 8 weeks starting at 8 weeks of age. (A) Pre-HFD fasting serum levels of total 
cholesterol, free cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) in 8-week-old Apoe-/-
LmnaLCS/LCS mice (n=5), Apoe-/-LmnaLCS/LCSSM22αCre mice (n=4), and Apoe-/-LmnaLCS/LCSLysMCre mice (n=6). (B) Post-
HFD fasting serum levels of total cholesterol, free cholesterol, LDL, and HDL in 16-week-old Apoe-/-LmnaLCS/LCS mice 
(n=10), Apoe-/-LmnaLCS/LCSSM22αCre mice (n=7), and Apoe-/-LmnaLCS/LCSLysMCre mice (n=7). Data are shown as mean ± 
SEM. Statistical differences were analyzed by one-way ANOVA with Tukey´s post hoc test. 
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Figure 16. Apoe-/-LmnaLCS/LCSSM22αCre and Apoe-/-LmnaLCS/LCSLysMCre mice show normal hematological 
parameters. Mice were fed high-fat diet (HFD) for 8 weeks starting at 8 weeks of age. (A) Pre-HFD (fasting) hematology 
results for 8-week-old Apoe-/-LmnaLCS/LCS mice (n=17), Apoe-/-LmnaLCS/LCSSM22αCre mice (n=11), and Apoe-/-
LmnaLCS/LCSLysMCre mice (n=11). (B) Post-HFD (fasting) hematology results for 16-week-old Apoe-/-LmnaLCS/LCS mice 
(n=17), Apoe-/-LmnaLCS/LCSSM22αCre mice (n=11), and Apoe-/-LmnaLCS/LCSLysMCre mice (n=11). Data are shown as median 
with interquartile range and minima and maxima. Statistical differences were analyzed by one-way ANOVA with Tukey´s 
post hoc test. 
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Atherosclerosis burden in the thoracic aorta was similar between Apoe-/-LmnaLCS/LCSLysMCre 
and Apoe-/-LmnaLCS/LCS mice. By contrast, lesion burden in Apoe-/-LmnaLCS/LCSSM22αCre mice was 3.7-
fold higher (Fig. 17A). Moreover, histological analysis of Apoe-/-LmnaLCS/LCSSM22αCre mice revealed 
the same marked aortic phenotype as observed in the ubiquitous progeroid model, including massive 
VSMC loss, adventitial thickening, elastin structure changes, and medial lipid accumulation (Fig. 17B, 
C).  
 
Figure 17. Vascular smooth muscle cell (VSMC)-specific progerin expression in fat-fed Apoe
-/-
Lmna
LCS/LCS
SM22αCre 
mice triggers severe vascular pathology, including atherosclerosis, VSMC loss, lipid retention in the media and 
adventitial thickening. Mice were fed high-fat diet (HFD) for 8 weeks starting at 8 weeks of age. (A) Representative 
examples of thoracic aortas stained with Oil Red O (ORO); the graph shows quantification of atherosclerosis burden in 
Apoe
-/-
Lmna
LCS/LCS
 mice (n=24) Apoe
-/-
Lmna
LCS/LCS
SM22αCre mice (n=17), and Apoe
-/-
Lmna
LCS/LCS
LysMCre mice (n=19). 
(B) Representative staining of aorta sections with ORO and hematoxylin & eosin (H&E); graphs show quantification of 
lipid content in atheroma-free zones of the media (% of ORO-positive area) and adventitia-to-media thickness ratio; n=6-
8. Scale bar, 50 µm. (C) Representative immunofluorescence images of aortas stained with anti-smooth muscle actin (Sma) 
antibody (red) and Hoechst3442 (blue); graphs show quantification of VSMC content in the media as either % of Sma-
positive area (top) or nucleus count (bottom); n=6-8. Scale bar, 50 µm. Box and whisker plots in A and B show medians, 
interquartile range, and minima and maxima; data in C are mean ± SEM. Statistical analysis was performed by one-way 
ANOVA with Tukey´s post hoc test in A, B, and C. ***P<0.001, m: media, a: adventitia. 
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The above results provide the first direct evidence that restricting progerin expression to 
VSMCs is sufficient to accelerate atherosclerosis and reduce lifespan, offering the possibility to study 
CVD independently of other premature aging symptoms. Another advantage of Apoe-/-
LmnaLCS/LCSSM22αCre animals is the lack of overt growth defects, which may permit diagnostic 
techniques and interventional strategies that are unattainable in the undersized Apoe-/-LmnaG609G/G609G 
model. 
 
IV.3. Progerin triggers plaque vulnerability 
Previous studies have shown that loss of VSMCs in the tunica media may lead to changes in 
the composition and stability of atherosclerotic plaques (159). We therefore performed a more in-depth 
analysis of atheromata in the aortic root of Apoe-/-LmnaG609G/G609G and Apoe-/-LmnaLCS/LCSSM22αCre 
mice and their respective controls. Three different zones of the aortic root were analyzed, at the 
beginning, in the middle, and at the end of the aortic valve. Consistent with our previous results in the 
aorta (Fig. 5 and 17), we observed a higher atherosclerosis burden in both progeria models than in the 
respective controls, and this was accompanied by fibrosis and inflammation of the adjacent cardiac 
tissue (Fig. 18A, B). Moreover, a greater percentage of the aortic surface was affected by the 
atherosclerosis process in both Apoe-/-LmnaG609G/G609G and Apoe-/-LmnaLCS/LCSSM22αCre mice (Fig. 
18A, B). Importantly, all Apoe-/-LmnaG609G/G609G and Apoe-/-LmnaLCS/LCSSM22αCre mice exhibited 
coronary VSMC loss (Fig. 18C, D), and some of them developed coronary atherosclerosis (data not 
shown). In addition, we observed aortic valve degeneration and plaque formation on the aortic valve 
leaflets in Apoe-/-LmnaG609G/G609G and Apoe-/-LmnaLCS/LCSSM22αCre mice, pathologies that were absent 
in control mice (Fig. 18A, B, and data not shown). 
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Figure 18. Fat-fed Apoe
-/-
Lmna
G609G/G609G
 and Apoe
-/-
Lmna
LCS/LCS
SM22αCre mice exhibit increased atherosclerosis 
in the aortic root together with inflammation of the adjacent cardiac tissue and coronary alterations (including 
vascular smooth muscle cell (VSMC) loss and thickening and inflammation of the adventitia). Mice were fed high-
fat diet (HFD) for 8 weeks starting at 8 weeks of age. Serial sections of the aortic root were made and 3 different regions 
were stained with Masson’s Trichrome. (A, B) Representative photographs of atheroma plaque in the aortic root of 
Apoe
-/-
Lmna
G609G/G609G
 (A) and Apoe
-/-
Lmna
LCS/LCS
SM22αCre mice (B), and their corresponding controls; graphs show 
quantification of plaque area, with each point representing mean from three different aortic root regions (n=5). Scale 
bar, 200 µm. Dashed lines indicate medial perimeter (the last layer of elastin), dotted lines indicate the luminal surface 
of the atheroma plaque. (C, D) Representative photographs of coronary artery of Apoe
-/-
Lmna
G609G/G609G (C) and Apoe
-/-
Lmna
LCS/LCS
SM22αCre mice (D), and their corresponding controls. Scale bar, 100 µm. Data in A and B are shown as 
mean ± SEM. Statistical analysis was performed by two-tailed t-test in A and B. **P<0.01, ***P<0.001. 
 
Importantly, Apoe-/-LmnaG609G/G609G and Apoe-/-LmnaLCS/LCSSM22αCre atheromata showed 
features of vulnerable plaques. Accordingly, plaques of Apoe-/-LmnaG609G/G609G and Apoe-/-
LmnaLCS/LCSSM22αCre mice contained erythrocytes, indicating healed plaque fissure (Fig. 19A, B, 
top), and some animals showed hemorrhage in the aortic valve itself (Fig. 19A, bottom). We also found 
evidence of thrombus formation (Fig. 19B, bottom), which might be related to plaque erosion.  
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Figure 19. Atherosclerotic plaques of fat-fed Apoe
-/-
Lmna
G609G/G609G
 and Apoe
-/-
Lmna
LCS/LCS
SM22αCre mice show 
evidence of disruption. Mice were fed high-fat diet (HFD) for 8 weeks starting at 8 weeks of age. Serial sections of the 
aortic root were made and 3 different regions were stained with Masson’s Trichrome. (A) An example of intraplaque (top) 
and intravalve hemorrhage (bottom) in Apoe
-/-
Lmna
G609G/G6090G
 mice. (B) An example of intraplaque hemorrhage (top) and 
thrombus formation (bottom) in Apoe
-/-
Lmna
LCS/LCS
SM22αCre mice. 
 
IV.4. Progerin expression accelerates atherosclerosis in Apoe-/- mice fed normal chow 
To gain insight into the kinetics of progerin-induced atherogenesis and to assess the role of 
cholesterol in this process, we performed experiments in mice fed normal chow. Histological 
examination of aortas from young, 8-week-old mice revealed no differences between the progeroid 
models and their controls, with tissue almost free of atherosclerosis and no obvious structural 
alterations (Fig. 20A, C, E). By contrast, atherosclerosis was evident in the thoracic aorta of 16-week-
old Apoe-/-LmnaG609G/G609G and Apoe-/-LmnaLCS/LCSSM22Cre mice, as well as regions with VSMC loss 
and increased collagen content (Fig. 20B, D, E). Notably, Apoe-/-LmnaLCS/LCSSM22Cre mice 
presented a marginally more pronounced vascular phenotype than Apoe-/-LmnaG609G/G609G mice, with 
lipid retention in the media and adventitial thickening (data not shown), probably due to normal food 
intake and the consequent cholesterol level similar to that of the control mice. 
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Figure 20. Vascular disease in 16-week-old but not 8-week-old Apoe
-/-
Lmna
G609G/G609G
 and Apoe
-/-
Lmna
LCS/LCS
SM22αCre mice fed normal chow. (A-D) Representative images of thoracic aortas stained with Oil Red O 
and quantification of atherosclerosis burden in mice of the indicated ages and genotypes. Controls for Apoe
-/-
Lmna
G609G/G609G
 
and Apoe
-/-
Lmna
LCS/LCS
SM22αCre mice were Apoe
-/-
Lmna
+/+
 and Apoe
-/-
Lmna
LCS/LCS
, respectively. The number of mice is 
indicated below each graph. (E) Representative histology sections of Masson´s Trichrome-stained aortic arches extracted 
from mice of the indicated ages and genotypes fed normal chow diet. White arrowheads indicate regions with vascular 
smooth muscle cell loss. Scale bar, 50 µm. Data in A-D are shown as median with interquartile range and minima and 
maxima. Statistical differences were analyzed by the two-tailed Mann-Whitney test. *P<0.05, **P<0.01. 
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Our findings in both the ubiquitous and the VSMC-specific progeric mouse models fed either 
normal chow or HFD indicate that VSMCs are particularly sensitive to progerin accumulation, which 
leads to cell damage and death that is accelerated in the presence of other stress stimuli, including high 
cholesterol (Fig. 21). Mechanical stress also seems to play an important role in this process because 
VSMC loss differs between distinct aortic regions and positively correlates with high shear stress (e.g., 
VSMC loss is higher in the aortic arch than in the thoracic aorta, data not shown). Dead VSMCs are 
replaced by extracellular matrix components, which retain lipids and lipoproteins. Additionally, pro-
inflammatory signals from dead cells may activate the vascular endothelium and enhance its 
permeability for the circulating lipoprotein particles. Cell debris and lipid/lipoprotein deposits trigger 
inflammation and thickening of the adventitia and accelerate atheroma plaque formation. Finally, 
vulnerable plaque disruption may lead to cardiovascular events, such as myocardial infarction, and 
cause premature death.  
 
Figure 21. Proposed mechanism of vascular smooth muscle cell (VSMC)-specific progerin toxicity leading to 
accelerated atherosclerosis and premature death. Progerin expression triggers VSMC death, which is accelerated in the 
presence of other stress stimuli, such as high cholesterol or high mechanical stress. Dead VSMCs are replaced with 
extracellular matrix, which retains more lipids and lipoproteins. This may create a vicious circle – the more lipids are 
accumulated in the media, the more VSMCs die (and vice versa). Cell death and lipid/lipoprotein deposits drive 
inflammation and thickening of the adventitia and accelerate atherosclerosis. Finally, vulnerable plaques lead to death, 
probably due to a cardiovascular event, such as myocardial infarction. 
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IV.5. Progerin expression in VSMCs leads to progressive hypotension 
The ubiquitous and VSMC-specific models of progeria presented a very similar aortic 
phenotype, both leading to aortic luminal dilatation and plaque buildup. We therefore hypothesized 
that progerin expression might affect blood pressure. To address this, mice were fed normal chow and 
blood pressure was measured at approximately 16 weeks of age during 5 consecutive days. Blood 
pressure was not different between Apoe-/-LmnaG609G/G609G mice and Apoe-/-Lmna+/+ controls (Fig. 
22A); however, Apoe-/-LmnaG609G/G609G mice developed severe bradycardia (Fig. 22A), which has been 
previously reported for progeroid LmnaG609G/G609G and Zmpste24-/- mice (30, 59). Furthermore, diastolic 
blood pressure in Apoe-/-LmnaLCS/LCSSM22Cre mice, which showed more pronounced vasculopathy, 
was significantly lower than in Apoe-/-LmnaLCS/LCS littermates (Fig. 22B). Follow-up of the Apoe-/-
LmnaLCS/LCSSM22Cre animals showed a further significant decline in both systolic and diastolic blood 
pressure at 26 weeks of age (Fig. 22C). 
These results conflict with findings in progeria patients. Specifically, two different studies 
reported an increased incidence of hypertension in HGPS children (17, 23); however, those results 
could be considered biased. In the first work by Merideth et al. only the highest blood pressure readings 
were reported, although this parameter was measured 6 times during the course of the study (17). It is 
puzzling why the authors elected to report and analyze only the maximum blood pressure values instead 
of the mean or median, raising concerns about the validity of their conclusions. The second study by 
Gerhard-Herman et al. reported that blood pressure values were increased in around 30% of the patients 
as compared with age-matched controls (23). When height-age standards were applied to account for 
the growth impairment, systolic and diastolic blood pressures were higher in approximately half of the 
patients. Nevertheless, the authors did not report how many normotensive and hypotensive children 
were in the studied cohort. They also did not provide extensive details about experimental design, for 
example, the number of times that blood pressure was measured and how the data were analyzed. In 
addition, some published reports describing HGPS phenotypes include as supplementary information 
all the blood pressure measurements registered during the study and many of these values are below 
the normal range for age-matched controls (20). Based on these observations in patients and our 
findings in mice, more studies are warranted to elucidate the effect of progerin on blood pressure in 
children with HGPS, with special emphasis on hypotension and occasional hypertension incidence. 
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Figure 22. Apoe-/-LmnaLCS/LCSSM22Cre mice develop progressive hypotension while Apoe-/-LmnaG609G/G609G mice 
display blood pressure and heart rate variability. Blood pressure and heart rate measurements were performed in 
conscious 16-week-old (for both progeria models) and 26-week-old (for VSMC-specific progeria model) mice fed normal 
chow diet. (A, B, C) Heart rate, systolic and diastolic blood pressure analysis for Apoe
-/-
Lmna
G609G/G609G
, Apoe
-/-
Lmna
LCS/LCS
SM22αCre, Apoe
-/-
Lmna
+/+
 and Apoe
-/-
Lmna
LCS/LCS
mice. (C, D, E) Variability in the heart rate, systolic and 
diastolic blood pressure for Apoe
-/-
Lmna
G609G/G609G
, Apoe
-/-
Lmna
LCS/LCS
SM22αCre, Apoe
-/-
Lmna
+/+
 and Apoe
-/-
Lmna
LCS/LCS
mice measured as coefficient of variation (CV). n=10-13. Data are presented as mean ± SEM. Statistical analysis 
was performed by two-tailed t-test. *P<0.05, **P<0.01, ***P<0.001. 
 
Although Apoe-/-LmnaG609G/G609G mice, unlike Apoe-/-LmnaLCS/LCSSM22Cre mice, did not 
develop prominent hypotension until 16 weeks of age, we observed a substantial instability and 
variability in heart rate and blood pressure (Fig. 22D-F). Blood pressure variability is defined as 
changes in blood pressure over time (hours, days, weeks, months etc.), whereas instability refers to 
transient oscillations in blood pressure, typically in response to pain, stress or change in posture, and 
adds to total variability. Variability and instability in blood pressure in humans is associated with higher 
risk of vascular events (such as stoke) related to plaque rupture (26, 27). Thus, blood pressure instability 
and variability in Apoe-/-LmnaG609G/G609G mice could be linked to intraplaque hemorrhages observed in 
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those animals upon HFD feeding (see subsection IV.3). However, intraplaque hemorrhages were also 
present in HFD-fed Apoe-/-LmnaLCS/LCSSM22Cre mice, which do not show blood pressure variability 
(at least at the same age). Since blood pressure measurements were performed in animals fed normal 
chow presenting only moderate vasculopathy, the relationship between plaque disruption and blood 
pressure variation in progeria mice should be further defined by preforming blood pressure analysis in 
HFD-fed progeroid mice.  
 
IV.6. Apoe-/-LmnaG609G/G609G mice develop arrhythmias 
 Blood pressure measurements in conscious Apoe-/-LmnaG609G/G609G mice revealed heart rate 
instability and variability, suggesting cardiac involvement (Fig. 22D). Moreover, a previous study has 
described electrical cardiac alterations in the Zmpste24-deficient (Zmpste24-/-) progeria mouse model 
(30). Given this information, we performed ECG in both ubiquitous and VSMC-specific progeria 
models. In accordance with the results from conscious animals (subsection IV.5), 16-week-old 
anesthetized Apoe-/-LmnaG609G/G609G mice presented severe bradycardia (Fig. 23A) together with 
prolonged QRS, QT and QTc intervals (Fig. 23A). Importantly, 3 out of 7 mice showed arrhythmias 
(Fig. 23B), which might explain the blood pressure instability and variability described in the previous 
subsection. This result is also consistent with the observation that HGPS patients show repolarization 
abnormalities resulting in an increased risk of arrhythmias and premature death (30). 
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Figure 23. Apoe-/-LmnaG609G/G609G mice develop cardiac electrical defects resulting in arrhythmias. Electrocardiogram 
(ECG) was performed in isoflurane-anesthetized 16-week-old mice fed normal chow. (A) ECG parameters for Apoe-/-
LmnaG609G/G609G (n=5) and Apoe-/-Lmna+/+ (n=7) mice. (B) Representative images of ECG recording for Apoe-/-Lmna+/+ (left) 
and Apoe-/-LmnaG609G/G609G (right) mice. Apoe-/-LmnaG609G/G609G mice exhibit bradycardia and arrhythmia. QRSH, PH, TH 
indicate amplitude of QRS complex, PH and TH waves, respectively. Data are presented as mean ± SEM. Statistical analysis 
was performed by two-tailed t-test. *P<0.05, **P<0.01, ***P<0.001. 
 
In contrast to the findings with Apoe-/-LmnaG609G/G609G mice, 16-week-old Apoe-/-
LmnaLCS/LCSSM22Cre mice did not present any evident ECG alterations (Fig. 24A). However, follow-
up of these animals revealed low voltage of QRS complex at 26 weeks of age (Fig. 24B), which might 
indicate loss of viable myocardial tissue, for example, due to myocardial infarction. Low QRS voltage 
on the ECG is a marker of the severity of heart failure, and is a risk factor for adverse outcomes in 
patients with this condition (160). Likewise, many of the Apoe-/-LmnaLCS/LCSSM22Cre mice exhibited 
T wave fattening or inversion (Fig. 24B and data not shown), further supporting the notion that these 
animals may have cardiac involvement as they age, probably associated with progressive 
atherosclerosis. Indeed, acute myocardial ischemia in mice has been related to the inverted T wave on 
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the ECG (161). Remarkably, studies in HGPS patients revealed ST depression/elevation and negative 
and biphasic T waves, especially evident at advanced stages of the disease (17, 30).  
 
Figure 24. Apoe-/-LmnaLCS/LCSSM22Cre mice show normal cardiac electrical function at 16 weeks of age and lower 
voltage of QRS complex and T wave at 26 weeks of age compared with Apoe-/-LmnaLCS/LCS littermates. 
Electrocardiogram (ECG) was performed in isoflurane-anesthetized 16- and 26-week-old mice fed normal chow diet. (A) 
ECG parameters for 16-week-old Apoe-/-LmnaLCS/LCSSM22Cre (n=7) and Apoe-/-LmnaLCS/LCS (n=7) mice. (B) ECG 
parameters for 26-week-old Apoe-/-LmnaLCS/LCSSM22Cre (n=8) and Apoe-/-LmnaLCS/LCS (n=7) mice. QRSH, PH, TH 
indicate amplitude of QRS complex, PH and TH waves, respectively. Data are presented as mean ± SEM. Statistical analysis 
was performed by two-tailed t-test. *P<0.05. 
 
IV.7. Apoe-/-LmnaLCS/LCSSM22Cre die from atherosclerosis-related causes 
Despite an almost identical vascular phenotype, ubiquitous and VSMC-specific atherosclerosis-
prone progeria models showed different median survival (18.5 weeks versus 34.3 weeks, respectively). 
Apoe-/-LmnaLCS/LCSSM22Cre mice, which did not display any overt aging phenotype, died suddenly 
between 26 and 66 weeks of age. Interestingly, LmnaLCS/LCSSM22αCre mice with an intact Apoe gene 
also presented VSMC loss and aortic adventitial thickening (Fig. 25A), but did not develop 
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atherosclerosis and had a normal life span (Fig. 25B). These findings point to progerin-driven 
atherosclerosis as the main cause of death in Apoe-/-LmnaLCS/LCSSM22Cre mice. By contrast, Apoe-/-
LmnaG609G/G609G mice progressively lost fat tissue, developed bone problems and muscle weakness, and 
died between 15 and 24 weeks of age, a median survival very similar to that of atherosclerosis-free 
LmnaG609G/G609G mice. These results strongly suggest that Apoe-/-LmnaG609G/G609G mice and 
LmnaG609G/G609G mice die from the same cause, which is probably independent of atherosclerosis. These 
observations, together with distinct cardiac alterations present in both atherosclerosis-susceptible 
progeria models, lead us to hypothesize that the cause of death is different in ubiquitous and VSMC-
specific progeria models, at least in the majority of the cases. 
 
Figure 25. LmnaLCS/LCSSM22αCre mice without atherosclerosis-susceptible background show aortic vascular smooth 
muscle cell loss and adventitial thickening but have normal lifespan. LmnaLCS/LCS mice were used as controls. (A) 
Representative histology sections of aortic arches stained with hematoxylin & eosin (H&E) and Masson´s Trichrome. Mice 
fed normal chow were sacrificed at 38 weeks of age. m: media, a: adventitia. Scale bar, 100 µm. (B) Kaplan-Meier survival 
curves of LmnaLCS/LCSSM22αCre mice (n=8) and LmnaLCS/LCS mice (n=10). Statistical differences in B were analyzed using 
the log-rank test. 
 
To analyze cardiovascular alterations, which may reveal the cause of death, we collected aorta, 
heart and brain from normal chow-fed Apoe-/-LmnaG609G/G609G and Apoe-/-LmnaLCS/LCSSM22Cre mice 
at an age close to their maximum survival (21-23 weeks for ubiquitous and 51 weeks for VSMC-
specific model). Atherosclerosis burden in the aortic arch and thoracic aorta was significantly higher 
in Apoe-/-LmnaG609G/G609G mice than in Apoe-/-Lmna+/+ controls (Fig. 26A). When Apoe-/-LmnaLCS/LCS 
and Apoe-/-LmnaLCS/LCSSM22Cre mice were compared, Apoe-/-LmnaLCS/LCSSM22Cre mice showed 
increased lesion formation in the thoracic aorta (Fig. 26B); however no significant differences were 
found in the aortic arch (Fig. 26B), likely because this athero-prone aortic region is saturated with 
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plaques at 51 weeks (1 year) of age. Importantly, vascular pathology was much more severe in Apoe-/-
LmnaLCS/LCSSM22Cre mice than in Apoe-/-LmnaG609G/G609G mice (Fig. 26C). 
 
Figure 26. Apoe-/-LmnaLCS/LCSSM22Cre mice have a more severe vascular phenotype than Apoe-/-LmnaG609G/G609G, 
both at ages close to their maximum survival. Mice were fed normal chow and sacrificed at 21-23 weeks of age (Apoe-/-
LmnaG609G/G609G and control Apoe-/-Lmna+/+ mice) and 51 weeks of age (Apoe-/-LmnaLCS/LCSSM22Cre and control Apoe-/-
LmnaLCS/LCS mice). (A) Representative aortas of Apoe
-/-
Lmna
G609G/G609G
 and Apoe
-/-
Lmna
+/+
 mice stained with Oil Red O 
(ORO); graphs show quantification of atherosclerosis burden in the aortic arch and thoracic aorta; n=6. (B) Representative 
aortas of Apoe-/-LmnaLCS/LCSSM22Cre and Apoe-/-LmnaLCS/LCS mice stained with ORO; graphs show quantification of 
atherosclerosis burden in the aortic arch and thoracic aorta; n=5-6. (C) Higher magnification of ORO-stained thoracic aortas 
of the indicated genotypes. Data are shown as median with interquartile range and minima and maxima. Statistical 
differences were analyzed by two-tailed Mann-Whitney test. *P<0.05, **P<0.01. 
 
We next performed a more detailed analysis of the atherosclerotic plaques in the aortic root. 
Both models exhibited aortic valve degeneration characterized by loss of cells and fibrosis (data not 
shown). Apoe-/-LmnaG609G/G609G plaques were generally immature with intraplaque hemorrhages, which 
were absent in the age-matched controls (Fig. 27). Two out of six Apoe-/-LmnaG609G/G609G animals 
showed signs of coronary atherosclerosis (data not shown). In Apoe-/-LmnaLCS/LCSSM22Cre mice, 
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atheromas were mature, severely calcified, and many of them presented chondroid metaplasia (Fig. 
27). The atheromas that were not calcified showed thin fibrous caps and large necrotic cores (Fig 27), 
characteristics of vulnerable plaques. The majority of analyzed Apoe-/-LmnaLCS/LCSSM22Cre mice 
developed coronary atherosclerosis (data not shown). 
 
Figure 27. Apoe-/-LmnaLCS/LCSSM22Cre mice have more severe atherosclerosis in the aortic root than Apoe-/-
LmnaG609G/G609G, both at ages close to their maximum survival. Mice were fed normal chow and sacrificed at 21-23 weeks 
of age (Apoe-/-LmnaG609G/G609G and control Apoe-/-Lmna+/+ mice) and 51 weeks of age (Apoe-/-LmnaLCS/LCSSM22Cre and 
control Apoe-/-LmnaLCS/LCS mice). Representative aortic root sections of Apoe
-/-
Lmna
G609G/G609G
, Apoe
-/-
Lmna
+/+
, Apoe-/-
LmnaLCS/LCSSM22Cre and Apoe-/-LmnaLCS/LCS mice stained with Masson´s Trichrome. Middle and bottom panels show 
higher magnification of atherosclerotic plaques. m: media, p: plaque.  
 
We also performed histopathological evaluation of the heart. Apoe-/-LmnaG609G/G609G hearts were 
characterized by cardiomyocyte vacuolization that was absent in Apoe-/-Lmna+/+, Apoe-/-
LmnaLCS/LCSSM22Cre and Apoe-/-LmnaLCS/LCS mice (Fig. 28). This feature was previously described 
in progeroid Zmpste24-/- mice (43). Importantly, cardiomyocyte vacuolization is frequently observed 
in the border zones of infarcted heart tissue and it is a marker of ischemic injury (162-164). 
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Figure 28. Apoe-/-LmnaG609G/G609G hearts exhibit cardiomyocyte vacuolization. Mice fed normal chow were sacrificed at 
21-23 weeks of age (close to their maximum survival). Photographs show hematoxylin & eosin-stained cardiac tissue of 
Apoe-/- Lmna+/+ (left) and Apoe-/- LmnaG609G/G609G (right) mice. Scale bar 200 µm. Black arrows indicate examples of 
cardiomyocyte vacuolization. 
 
Furthermore, two out of six Apoe-/-LmnaG609G/G609G hearts showed coronary atherosclerosis 
(Table 1) and a collagen scar in the septum, indicative of a non-fatal infarct (Fig. 29). Nevertheless, 
no alterations were detected in half of the animals analyzed (Table 1), except for vacuolization of 
cardiomyocytes. 
Genotype 
Intimal 
hyperplasia 
Coronary 
atherosclerosis 
Perivascular 
fibrosis 
Interstitial 
fibrosis 
Calcification 
Apoe-/-Lmna+/+ 1/6 0/6 0/6 0/6 0/6 
Apoe-/-LmnaG609G/G609G 3/6 2/6 0/6 2/6 0/6 
Apoe-/-LmnaLCS/LCS 2/6 1/6 1/6 0/6 0/6 
Apoe-/-LmnaLCS/LCSSM22Cre 4/5 4/5 5/5 5/5 2/5 
Table 1. Apoe-/-LmnaLCS/LCSSM22Cre mice exhibit a more severe cardiac phenotype than Apoe-/-LmnaG609G/G609G both 
at ages close to their maximum survival. Mice fed normal chow were sacrificed at 21-23 weeks of age for Apoe-/-
LmnaG609G/G609G (and control Apoe-/-Lmna+/+) and 51 weeks of age for Apoe-/-LmnaLCS/LCSSM22Cre (and control Apoe-/-
LmnaLCS/LCS) mice. Serial sections of the heart (at 6 different levels of the apex) were prepared and stained with hematoxylin 
& eosin and Masson´s Trichrome. Cardiac pathology was assessed in 5-6 mice per genotype. 
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Figure 29. Evidence of coronary atherosclerosis and myocardial infarction in Apoe-/- LmnaG609G/G609G mice. Mice fed 
normal chow were sacrificed at 21-23 weeks of age (close to their maximum survival). Photographs show consecutive 
sections of an Apoe-/- LmnaG609G/G609G heart stained with hematoxylin & eosin (H&E) and Masson´s trichrome, showing 
coronary atherosclerosis and infarct in the septum. Scale bar 1mm. RV: right ventricle; S: septum; LV: left ventricle. 
 
Examination of Apoe-/-LmnaLCS/LCSSM22Cre hearts revealed that the majority presented 
perivascular and interstitial fibrosis, coronary atherosclerosis and intimal hyperplasia (Table 1). We 
also found calcification of the coronary plaque in some of the animals analyzed (Table 1). These 
pathological alterations in the heart suggest that Apoe-/-LmnaLCS/LCSSM22Cre animals suffer many 
small infarcts during their lifetime, similar to HGPS patients. However, no evidence of stroke was 
found in the brain of Apoe-/-LmnaG609G/G609G and Apoe-/-LmnaLCS/LCSSM22Cre models (data not 
shown). 
In summary, comparison of mice at ages close to their maximum survival revealed a more 
severe cardiac phenotype and atherosclerotic disease in Apoe-/-LmnaLCS/LCSSM22Cre mice than in 
Apoe-/-LmnaG609G/G609G mice. The histopathological findings in the aorta and heart support our 
hypothesis that Apoe-/-LmnaLCS/LCSSM22Cre animals die of atherosclerosis complications, whereas 
Apoe-/-LmnaG609G/G609G die of atherosclerosis-independent processes. Plaque disruption leading to an 
infarct and subsequent death may occur in Apoe-/-LmnaG609G/G609G mice only if their survival is close to 
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26 weeks, the age at which Apoe-/-LmnaLCS/LCSSM22Cre begin to die. While we cannot rule out the 
possibility that Apoe-/-LmnaG609G/G609G mice die from heart failure, it is probably related to other 
complications such as arrhythmias (see subsection IV.6). 
 
IV.8. Progerin expression in VSMCs activates endoplasmic ER stress and the UPR 
In an attempt to identify mechanisms underlying the acceleration of atherosclerosis induced by 
progerin, we conducted a transcriptomic analysis of aortas from the ubiquitous and VSMC-specific 
progeria models. To identify drivers of disease rather than secondary changes, we collected arteries 
before the onset of overt disease. The appropriate age for collection was determined based on our 
previous histopathological analysis in Apoe-/-LmnaG609G/G609G and Apoe-/-LmnaLCS/LCSSM22Cre mice 
fed normal chow (subsection IV.4).  
Based on these findings and because VSMCs appear to be a major target of progerin, we 
performed RNA sequencing (RNAseq) on VSMC-rich media of disease-free aortas from 8-week-old 
Apoe-/-LmnaG609G/G609G and Apoe-/-LmnaLCS/LCSSM22Cre mice and their corresponding controls (Apoe-
/-Lmna+/+ and Apoe-/-LmnaLCS/LCS, respectively) (Fig. 30A). Four pooled samples per genotype were 
collected, and PCR analysis confirmed proper progerin and lamin A expression (Fig. 30B). Differential 
expression analysis revealed 776 significantly altered genes in the ubiquitous progeroid model and 931 
altered genes in the VSMC-specific model (Fig. 30C). Of these differentially-regulated genes, 240 
were common to both comparisons and had a high correlation (R2≈8, Fig. 30D).  
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Figure 30. Progerin expression in vascular smooth muscle cells (VSMCs) causes altered gene expression. (A) Sample 
preparation for RNA sequencing (RNAseq). (B) PCR confirmation of proper expression of lamin A and progerin in pooled 
medial aortas used for RNAseq. Arbp was used as endogenous control. (C) Bioinformatic analysis detected 776 
differentially expressed genes in medial aortas from Apoe-/- LmnaG609G/G609G mice with ubiquitous progerin expression 
compared with Apoe-/-Lmna+/+ control mice expressing wild-type lamin A/C and 931 genes in medial aortas from Apoe-/-
LmnaLCS/LCSSM22αCre mice with VSMC-specific progerin expression compared with Apoe-/-LmnaLCS/LCS control mice 
expressing lamin C only. There were 176 genes differentially expressed between the two control groups. The Venn diagram 
shows the overlap between sets of deferentially expressed genes identified in each of the 3 comparisons. (D) Correlation 
between logarithms of fold change calculated for the 240 genes shared between the comparisons “ubiquitous progerin vs 
wild-type lamin A/C” and “VSMC-specific progerin vs lamin C only“. 
 
To specifically separate the effect of progerin production from the absence of lamin A, we 
performed analysis of the two controls, which revealed 176 genes differentially expressed between 
Apoe-/-LmnaLCS/LCS aortas (expressing lamin C only) and Apoe-/-Lmna+/+ aortas (expressing wild-type 
lamin A/C) (Fig. 30C). However, there was hardly any overlap between the gene sets affected by 
progerin production in Apoe-/-LmnaG609G/G609G and Apoe-/-LmnaLCS/LCSSM22Cre mice and those 
influenced by the absence of lamin A in Apoe-/-LmnaLCS/LCS mice (Fig. 30C). Likewise, progerin and 
the absence of lamin A affected different pathways (Fig. 31). 
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Figure 31. Pathways affected by lack of lamin A do not overlap with those induced by progerin expression. Stacked 
bar charts representing pathways significantly changed after applying the Benjamini-Hochberg correction for multiple 
testing in 3 comparisons: (A) Apoe-/-LmnaG609G/G609G (ubiquitous progerin) vs Apoe-/-Lmna+/+ (ubiquitous lamin A and lamin 
C), (B) Apoe-/-LmnaLCS/LCSSM22αCre (vascular smooth muscle cell (VSMC)-specific progerin) vs Apoe-/-LmnaLCS/LCS 
(ubiquitous lamin C, no lamin A), and (C) Apoe-/-LmnaLCS/LCS (ubiquitous lamin C, no lamin A) vs Apoe-/- Lmna+/+ 
(ubiquitous lamin A and lamin C). The numbers of genes in each category (from the Ingenuity Pathway Analysis data base) 
are indicated above the bars. 
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Comparison analysis identified four pathways that were significantly altered in both the 
ubiquitous and the VSMC-specific progeroid models: fibrosis, nuclear factor erythroid 2-like 2 
(NRF2)-mediated oxidative stress, the ER stress response, and the UPR (Fig. 32, left: Canonical 
pathways). We also examined the predicted activation status of upstream regulators based on the 
expression of their target genes. This analysis revealed that the most differentially regulated factors 
belong to the ER stress response and ER stress-related UPR, for example, XBP1, ATF4 and DDIT3 
(Fig. 32, right: Upstream regulators). 
 
Figure 32. Progerin expression in vascular smooth muscle cell (VSMC)-rich aortic media activates endoplasmic 
reticulum (ER) stress and unfolded protein response (UPR). RNAseq results were analyzed using Ingenuity Pathway 
Analysis: (left) canonical pathway heatmap, showing processes affected by progerin expression in VSMC-rich medial 
aortas. Asterisk (*) indicates pathways which are significantly changed in both comparisons after applying the Benjamini-
Hochberg correction for multiple testing; (right) upstream regulator heatmap, showing predicted activation states of 
transcriptional regulators (black boxes indicate key molecules involved in ER stress and UPR regulation). 
 
 
IV. RESULTS AND DISCUSSION 
76 
 
To validate the RNAseq results, we performed quantitative real-time PCR on selected ER stress 
response and UPR genes that were significantly upregulated in aortic media from 8-week-old mice of 
both progeria models (Fig. 33A). This analysis confirmed progerin-induced upregulation of Calr, 
Ddit3, Dnajb9, Hspa5, Hsp90b1, and Pdia4 in VSMC-rich aortic media in both models (Fig. 33B, C). 
 
Figure 33. Endoplasmic reticulum (ER) stress and unfolded protein response (UPR) activation in progerin-
expressing aortas from Apoe
-/-
Lmna
G609G/G609G
 mice (ubiquitous progerin) and Apoe
-/-
Lmna
LCS/LCS
SM22αCre mice 
(vascular smooth muscle cell (VSMC)-specific progerin). (A) Six ER stress/UPR pathway genes selected for qPCR 
validation from among of those detected as differentially expressed in RNAseq in both models. (B, C) qPCR results in 
pooled medial aortas (n=4) obtained from 8-week-old Apoe
-/- 
Lmna
G609G/G609G
 mice (B) and Apoe
-/-
Lmna
LCS/LCS
SM22αCre 
mice (C) and their corresponding controls. Hprt and Gusb were used for normalization. Data are mean ± SEM. Statistical 
differences were analyzed by one-tailed t-test. *P<0.05, **P<0.01, ***P<0.001. 
 
We next assessed whether progerin activates the ER stress response and the UPR in other 
organs. Consistent with the ubiquity of progerin expression in Apoe-/-LmnaG609G/G609G mice, induction 
of ER stress response and the UPR was noted in some organs of these animals, with kidney being the 
organ most affected and liver the least (Fig. 34A). As anticipated, no activation of this stress pathway 
was detected in kidney, liver, spleen, or heart from Apoe-/-LmnaLCS/LCSSM22Cre mice, confirming the 
specificity of the model (Fig. 34B). The variability in the ER stress and UPR activation across the 
organs of Apoe-/-LmnaG609G/G609G mice may be in part attributed to different lamin A (and thus progerin) 
expression levels associated with tissue stiffness (63, 64). Moreover, distinct organs and tissues may 
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have different thresholds for tolerating misfolded protein load and therefore be more prone or resistant 
to ER stress. 
 
Figure 34. Endoplasmic reticulum (ER) stress and unfolded protein response (UPR) activation in different organs 
from Apoe
-/-
Lmna
G609G/G609G
 mice with ubiquitous progerin expression. qPCR results in organs from 8-week-old Apoe
-/-
Lmna
G609G/G609G
 mice (A) and Apoe
-/-
Lmna
LCS/LCS
SM22αCre mice (B) and their corresponding controls (n=4 per condition). 
Activation of some ER stress and UPR genes was observed in kidney, heart, and spleen of Apoe
-/-
Lmna
G609G/G609G
 mice but 
not in the same organs of Apoe
-/-
Lmna
LCS/LCS
SM22αCre mice. Hprt and Gusb were used for normalization. Data are mean ± 
SEM. Statistical differences were analyzed by two-tailed t-test. *P<0.05, **P<0.01, ***P<0.001. 
 
Previous in vitro and in vivo studies have identified numerous pathways potentially contributing 
to HGPS. Most of them, however, are mutually dependent, making it challenging to distinguish primary 
from secondary mechanisms. Our RNAseq analysis of pre-disease aortic media from the ubiquitous 
and VSMC-specific progeria models identified the ER stress response and the related UPR as potential 
driver mechanisms of atherosclerosis in progeria. We hypothesize that accumulation of misfolded 
progerin due to defective post-translational processing triggers ER stress in VSMCs, which might be 
exaggerated by medial deposits of lipids, also known to activate ER stress (165, 166). At early stages, 
VSMCs attempt to restore homeostasis by activating the UPR, but cell death occurs when stress cannot 
be resolved. Because of continuous crosstalk between stress pathways, ER stress can lead to activation 
of other stress responses. For instance, ER stress can sensitize cells to DNA damage-induced apoptosis 
(167), providing a possible link between our findings and those of previous studies showing increased 
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DNA damage in HGPS cells (101). In accordance with recent studies in HGPS fibroblasts, which 
identified the NRF2 pathway as a major progerin target (168), our RNAseq analysis detected NRF2-
mediated oxidative stress response as one of the main pathways affected by progerin expression in 
VSMCs. Oxidative stress induced by NRF2 is connected to ER stress through the protein kinase PERK, 
which phosphorylates the transcription factor NRF2 in response to ER stress (169). Moreover, ER 
stress is associated with inflammation, autophagy and mitochondrial dysfunction (170), processes that 
are affected in progeria (171-173). Our results identify an important upstream mechanism in VSMCs, 
which may link various stress pathways previously described in progeria. In vitro studies are thus 
warranted to further explore in detail the mechanisms linking ER stress, UPR and VSMC death in the 
setting of progeria, and the role of oxidized LDLs in this process. These studies could be performed 
with primary VSMCs from wild-type and progerin-expressing mice, and VSMCs differentiated from 
control and HGPS iPSCs (available from The Progeria Research Foundation). 
 
IV.9. Therapeutic effects of ER stress response targeting in progeroid mice  
Our RNAseq results strongly suggested a key role of ER stress response and the UPR as drivers 
of progerin-induced VSMC death and enhanced atherosclerosis in the ubiquitous and VSMC-specific 
progeria models. We therefore examined the potential benefits of targeting this pathway by chemical 
chaperone treatment. We selected TUDCA, a bile acid previously proven to efficiently alleviate ER 
stress and ameliorate experimental diabetes (174), aortic valve calcification (175), and myocardial 
infarction (176).  
Before using progeric mice, we conducted a pilot study with Apoe-/-Lmna+/+ control mice fed 
normal chow to monitor for any adverse effects of prolonged TUDCA treatment. Animals received 
TUDCA (400 mg/kg) or PBS intraperitoneal injections 3 times weekly starting at 6 weeks of age. 
TUDCA- and PBS-treated mice appeared healthy and did not show any overt pathology. However, 
weight gain in the TUDCA-treated group was slightly diminished (Fig. 35A), likely due to an increase 
in energy expenditure, as described previously by da-Silva et al. (177). Analysis at 26 weeks of age 
revealed similar blood pressure in both experimental groups (Fig. 35B), and the absence of blood 
pressure and heart rate instability and variability (Fig. 35C). Similarly, except for a borderline 
significant reduction in the PR segment in TUDCA-treated mice, all ECG parameters at 26 weeks of 
age were similar in both experimental groups (Fig. 35D).  
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Figure 35. Prolonged tauroursodeoxycholic acid (TUDCA) treatment of Apoe-/-Lmna+/+ mice does not cause any 
severe alteration in blood pressure or electrocardiogram (ECG) parameters. Apoe-/-Lmna+/+ mice fed normal chow 
received either TUDCA (400 mg/kg) or PBS intraperitoneal injections 3 times a week starting at 6 weeks of age. (A) Body 
weight curves for TUDCA-treated and untreated mice. P<0.0001 (B) Heart rate, systolic and diastolic blood pressure 
analysis for TUDCA-treated and untreated mice at 26 weeks of age. (C) Variability in the heart rate, systolic and diastolic 
blood pressure for 26-week-old TUDCA-treated and untreated mice measured as coefficient of variation (CV). (D) ECG 
parameters for 26-week-old TUDCA-treated and untreated mice. n=5. Data are presented as mean ± SEM. Statistical 
analysis was performed by two-tailed t-test. 
 
Necropsies of 27-week-old TUDCA- and PBS-treated mice did not reveal pathology in the 
intraperitoneal cavity (Fig. 36A), which might arise because of the multiple injections or the drug per 
se. We next analyzed the effect of TUDCA on atherosclerosis development as Erbay et al. found that 
the chemical chaperone 4-phenyl butyric acid (PBA) can delay atherosclerotic plaque formation via 
alleviating ER stress in macrophages (178). Importantly, this effect of PBA on atherosclerosis was 
independent of changes in lipids, lipoprotein profiles, glucose and insulin levels in the circulation (178). 
In agreement with these findings, we found a weak tendency toward reduced atherosclerosis in the 
aortic arch in mice treated with TUDCA, although differences did not reach statistical significance 
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(Fig. 36B). Our pilot study also revealed similar fasting serum levels of total and free cholesterol in 
both experimental groups, and significantly lower LDL in TUDCA-treated animals (Fig. 36C). 
 
Figure 36. Prolonged tauroursodeoxycholic acid (TUDCA) treatment of Apoe-/-Lmna+/+ mice does not significantly 
affect atherosclerosis and has only minor effect on the lipid profile. Apoe-/-Lmna+/+ mice fed normal chow received 
either TUDCA (400 mg/kg) or PBS intraperitoneal injections 3 times a week starting at 6 weeks of age. Mice were sacrificed 
at 27 weeks of age. (A) Representative photographs of intraperitoneal cavity of TUDCA-treated and untreated mice. (B) 
Representative images of Oil Red O-stained aortas of TUDCA-treated and untreated mice; graphs show quantification of 
atherosclerosis burden in aortic arch and thoracic aorta. (C) Fasting serum levels of total cholesterol, free cholesterol, low-
density lipoprotein (LDL), and high-density lipoprotein (HDL) in 27-week-old TUDCA-treated and mice. n=5. Data in B 
are shown as median; data in C are mean ± SEM. Statistical differences were analyzed by two-tailed Mann-Whitney test in 
B and two-tailed t-test in C. *P<0.05. 
 
We also observed that TUDCA induced some minor changes in the hematological parameters, 
including higher lymphocyte and lower monocyte percentage (Fig. 37). Whether these alterations are 
a cause or a consequence of diminished atherosclerosis burden should be addressed in a future study. 
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Figure 37. Prolonged tauroursodeoxycholic acid (TUDCA) treatment of Apoe-/-Lmna+/+ mice does not cause any 
significant alterations in hematological parameters. Apoe-/-Lmna+/+ mice fed normal chow received either TUDCA (400 
mg/kg) or PBS intraperitoneal injections 3 times a week starting at 6 weeks of age. Hematology (fasting) results for 27-
week-old TUDCA-treated and untreated (PBS) mice; n=5. Data are shown as median. Statistical differences were analyzed 
by two-tailed Mann-Whitney test. 
 
After confirming that prolonged TUDCA treatment did not trigger any deleterious side effects, 
we performed experiments with ubiquitous and VSMC-specific progeroid mouse models. Animals 
were fed HFD for 8 weeks starting at 8 weeks of age. Additionally, mice received intraperitoneal 
injections of TUDCA (400 mg/kg) 3 times weekly starting at 6 weeks of age in the case of Apoe-/-
LmnaG609G/G609G and Apoe-/-Lmna+/+ or at 8 weeks of age in the case of Apoe-/-LmnaLCS/LCSSM22Cre 
and Apoe-/-LmnaLCS/LCS mice. Control mice received PBS injections. TUDCA treatment in both HFD-
fed Apoe-/-LmnaG609G/G609G and Apoe-/-LmnaLCS/LCSSM22Cre mice inhibited atheroma lesion formation 
in the thoracic aorta (Fig. 38A, B) and alleviated aortic VSMC loss and adventitial thickening (Fig. 
38C-F). 
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Figure 38. Tauroursodeoxycholic acid (TUDCA) treatment alleviates vascular pathology in progeroid mouse models. 
Mice were treated with TUDCA or vehicle (PBS), starting at 6 weeks of age for Apoe
-/-
Lmna
+/+ 
and Apoe
-/-
Lmna
G609G/G609G
 
mice, and at 8 weeks of age for Apoe
-/-
Lmna
LCS/LCS
 and Apoe
-/-
Lmna
LCS/LCS
SM22αCre mice. All mice were fed high-fat diet 
for 8 weeks starting at 8 weeks of age. (A, B) Representative images of thoracic aortas stained with Oil Red O and 
quantification of atherosclerosis burden in TUDCA-treated and untreated mice of the indicated genotypes (n=7-8 in A; n=6-
8 in B). (C, D) Representative immunofluorescence images of aortas stained with anti-smooth muscle actin (Sma) antibody 
(red) and Hoechst3442 (blue). Graphs show quantification of vascular smooth muscle cell (VSMC) content in the media as 
either % of Sma-positive area (top) or number of nuclei/mm2 (bottom); n=6 in C (Apoe
-/-
Lmna
G609G/G609G
), and n=4-5 in D 
(Apoe
-/-
Lmna
LCS/LCS
SM22aCre). Scale bar, 50 µm. (E, F) Representative histology sections of hematoxylin & eosin (H&E)-
stained aortas. Graphs show quantification of adventitia-to-media thickness ratio; n=6 in E (Apoe
-/-
Lmna
G609G/G609G
), and 
n=4-5 in F (Apoe
-/-
Lmna
LCS/LCS
SM22aCre). Scale bar, 100 µm. Data in A, B, E and F are shown as median with interquartile 
range and minima and maxima; data in C and D are mean ± SEM. Statistical differences were analyzed by one-way ANOVA 
with Tukey´s post hoc test in A and B, one-tailed t-test in C and D, and one-tailed Mann-Whitney test in E and F. *P<0.05, 
**P<0.01, ***P<0.001. m: media, a: adventitia. 
 
We next examined the effect of TUDCA on survival. Notably, TUDCA prolonged the median 
lifespan of Apoe-/-LmnaLCS/LCSSM22Cre mice by 35% (median survival: 61.4 weeks in TUDCA-
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treated versus 45.35 weeks in untreated mice, P=0.0148), without affecting the survival of Apoe-/-
LmnaG609G/G609G mice (Fig. 39A).  
 
Figure 39. Tauroursodeoxycholic acid (TUDCA) treatment extends lifespan in Apoe
-/-
Lmna
LCS/LCS
SM22αCre mice. 
Mice were treated with TUDCA or vehicle (PBS), starting at 6 weeks of age for Apoe
-/-
Lmna
+/+ 
and Apoe
-/-
Lmna
G609G/G609G
 
mice, and at 8 weeks of age for Apoe
-/-
Lmna
LCS/LCS
 and
 
Apoe
-/-
Lmna
LCS/LCS
SM22αCre mice. Graphs show Kaplan-Meier 
survival (A) and body weight (B) curves of TUDCA-treated and untreated (PBS) mice of the indicated genotypes (n=7-8 
Apoe
-/-
Lmna
G609G/G609G
 mice; n=11-12 Apoe
-/-
Lmna
LCS/LCS
SM22αCre mice); P=0.0148 for TUDCA-treated vs untreated 
Apoe
-/-
Lmna
LCS/LCS
SM22αCre mice (median survival: 61.4 vs 45.35 weeks, respectively). Data in B are mean ± SEM. 
Statistical differences were analyzed by log-rank test in A. 
 
These results show that whereas TUDCA treatment ameliorated vasculopathy in both progeria 
models, it failed to prolong lifespan in mice ubiquitously expressing progerin. In accord with this 
finding, ePPi treatment was shown to prevent vascular calcification in LmnaG609G/G609G mice, but had 
no effect on survival (60). This result may be explained by our previous studies on the cause of death 
of progeric mice, showing that Apoe-/-LmnaLCS/LCSSM22Cre mice, unlike Apoe-/-LmnaG609G/G609G mice, 
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die of atherosclerosis-related causes. Thus, prevention of atherosclerosis by TUDCA in Apoe-/-
LmnaLCS/LCSSM22Cre mice was also associated with a significant prolongation of lifespan. 
Although we did not detect any evident adverse effects of TUDCA treatment, we did observe 
that weight gain was lower in TUDCA-treated groups than in PBS-injected groups (Fig. 35A and Fig. 
39B). Even though this diminished weight gain was usually not significant, it was present across 
different experiments in all analyzed genotypes and was independent of diet. This observation is in 
agreement with the work of da-Silva et al., who showed that some chemical chaperones, including 
TUDCA, accelerate thyroid hormone activation and energy expenditure (177). Remarkably, progerin 
can also increase energy expenditure and mitochondrial activity, contributing to lipodystrophy; thus, 
caution should be exercised when calculating the TUDCA dose for progeric mice, to avoid possible 
harmful effects on adipose tissue. Nevertheless, four weeks of oral TUDCA treatment in obese patients 
was shown not to alter body weight and total body fat, indicating that the doses used in humans (1750 
mg/day/person in this particular study) are unlikely to affect body weight and adipose tissue 
homeostasis (179). 
The chemical chaperone TUDCA is a water-soluble bile acid that has been used successfully in 
Europe to treat cholestatic liver disease (180, 181). TUDCA represents around 0.13% of the bile acid 
pool in human serum (182), and is a high-abundance bile acid in American and Asiatic black bears 
(183). Various studies reported no adverse effects of TUDCA treatment (daily doses from 500 to 1750 
mg per person) in obese, liver-transplanted, and primary biliary cirrhosis patients (179, 184-186). In 
general, chemical chaperones show exceptional in vivo safety, and some of them have been approved 
for clinical use by the U.S. Food and Drug Administration, for example, PBA for urea cycle disorders 
(187, 188) and ursodeoxycholic acid or primary biliary cirrhosis (189-191). Importantly, chemical 
chaperones have been used successfully in children (187, 188). Thus, the potential of chemical 
chaperone treatment to ameliorate atherosclerosis and associated ischemic events should be explored 
in children with HGPS. The use of a combination of drugs targeting different pathways may be an 
effective, therapeutic strategy until approaches directly targeting progerin production become available 
in humans. 
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In this PhD thesis, I have generated new mouse models to study the role of progerin in accelerating 
atherosclerosis and premature death, and to identify the underlying mechanisms and develop new 
therapies for the treatment of progeria in mice. The main conclusions derived from this thesis are the 
following: 
1. Apoe-/- LmnaG609G/G609G mice with ubiquitous progerin expression display features of premature 
aging (shortened life span, reduced body weight, etc.), and exhibit early onset of vascular 
disease (including enhanced atherosclerosis, VSMC loss, increased lipid and collagen content 
in the media, and adventitial thickening). As these alterations mimic the main symptoms of 
HGPS, these mice constitute the first available preclinical model to study atherosclerosis in the 
context of HGPS. 
2. Apoe-/- LmnaLCS/LCS SM22αCre mice with VSMC-specific progerin expression do not exhibit 
premature aging, but present the same vasculopathies as those observed in the ubiquitous 
progeria model (including accelerated atherosclerosis, VSMC loss, lipid retention in the media, 
adventitial thickening, etc.), and shortened life span. These findings demonstrate that progerin 
effects on VSMCs play a crucial role in CVD progression and premature death in HGPS. 
3. Apoe-/- LmnaLCS/LCS LysMCre mice with macrophage (myeloid)-specific progerin expression do 
not show any premature aging or vascular phenotype. 
4. Atherosclerotic lesions in Apoe-/- LmnaG609G/G609G and Apoe-/- LmnaLCS/LCS SM22αCre mice 
display characteristic features of vulnerable plaques, which may lead to myocardial infarction. 
5. Apoe-/- LmnaLCS/LCS SM22αCre mice develop hypotension as they age. 
6. Apoe-/- LmnaG609G/G609G mice, unlike Apoe-/- LmnaLCS/LCS SM22αCre mice, develop early cardiac 
electrical defects (prolonged QRS complex, QT and QTc intervals) and arrhythmias, which can 
lead to premature death. 
7. Apoe-/- LmnaLCS/LCS SM22αCre mice, unlike Apoe-/- LmnaG609G/G609G mice, die of 
atherosclerosis-related causes. 
8. High-throughput RNAseq analysis identified ER stress response and the subsequent UPR as 
major alterations in the tunica media of both Apoe-/- LmnaG609G/G609G and Apoe-/- LmnaLCS/LCS 
SM22αCre mice. 
9. Targeting ER stress response and the UPR with the chemical chaperone TUDCA inhibits 
atherosclerosis, VSMC loss and adventitial thickening in Apoe-/- LmnaG609G/G609G and Apoe-/- 
LmnaLCS/LCS SM22αCre mice, and extends lifespan in the VSMC-specific model by 35%. These 
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findings establish the ER stress response and the UPR as driver mechanisms of progerin-
induced VSMC death and accelerated atherosclerosis. 
 
In summary, our results with progeroid mouse models suggest the possibility of chemical 
chaperone treatment for ameliorating atherosclerosis in children with HGPS. Since premature and 
physiological aging share many pathologies (including CVD), and progerin has been detected at low 
levels in cells and tissues of normally aging individuals, research on HGPS might shed light on the 
mechanisms of normal aging. 
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En esta tesis doctoral hemos generado nuevos modelos de ratón para estudiar el papel de la progerina 
en la aceleración de la aterosclerosis y la muerte prematura asociada a HGPS. Además, hemos 
identificado los mecanismos subyacentes y hemos desarrollado nuevas terapias para tratar la 
enfermedad en ratones progéricos. Las principales conclusiones derivadas de esta tesis son: 
1. Los ratones Apoe-/- LmnaG609G/G609G con expresión ubicua de progerina muestran características 
de envejecimiento prematuro (pérdida de peso corporal, menor longevidad, etc.) y desarrollan 
con mucha rapidez enfermedad vascular (incluyendo aterosclerosis acelerada, pérdida de 
CMLVs, aumento del contenido de colágeno y retención de lípidos en la capa media, y fibrosis 
de la capa adventicia). Dado que estas alteraciones recapitulan los principales síntomas del 
HGPS, estos ratones son el primer modelo preclínico disponible para estudiar la aterosclerosis 
en el contexto de HGPS. 
2. Los ratones Apoe-/-LmnaLCS/LCS SM22αCre con expresión de progerina específica en CMLVs no 
muestran fenotipo progérico, pero presentan las mismas alteraciones vasculares observadas en 
el modelo de expresión ubicua de progeria, incluyendo aterosclerosis acelerada, pérdida de 
CMLVs, retención de lípidos en la capa media y fibrosis de la capa adventicia, así como menor 
longevidad. Estos hallazgos demuestran que los efectos de la progerina en las CMLVs juegan 
un papel crítico en la progresión de la ECV y la muerte prematura asociadas a HGPS. 
3. Los ratones Apoe-/-LmnaLCS/LCS LysMCre con expresión de progerina específica en macrófagos 
(línea mieloide) no muestran envejecimiento prematuro ni patología vascular. 
4. Las lesiones ateroscleróticas en ratones Apoe-/- LmnaG609G/G609G y Apoe-/-LmnaLCS/LCS SM22αCre 
presentan características de placas vulnerables, que pueden provocar infarto de miocardio. 
5. Los ratones Apoe-/-LmnaLCS/LCS SM22αCre desarrollan hipotensión a medida que envejecen. 
6. Los ratones Apoe-/- LmnaG609G/G609G, a diferencia de Apoe-/-LmnaLCS/LCS SM22αCre, desarrollan 
tempranamente alteraciones electrocardiográficas (prolongación del complejo QRS, y de los 
intervalos QT y QTc) y arritmias. Estas anomalías pueden provocar muerte prematura. 
7. Los ratones Apoe-/-LmnaLCS/LCS SM22αCre, a diferencia de Apoe-/- LmnaG609G/G609G, mueren por 
problemas relacionadas con la aterosclerosis. 
8.  Mediante RNAseq hemos identificado un aumento significativo de genes implicados en el 
estrés de RE y la respuesta a proteínas desplegadas (UPR) en la túnica de media de ratones con 
expresión de progerina ubicua (Apoe-/- LmnaG609G/G609G) y específica de CMLVs (Apoe-/-
LmnaLCS/LCS SM22αCre). 
V. CONCLUSIONES 
96 
 
9. El tratamiento con TUDCA, una chaperona química que mejora la supervivencia celular en 
situaciones de estrés de RE y UPR, inhibe la aterosclerosis, la pérdida de CMLVs y el 
engrosamiento de la adventicia en ratones Apoe-/- LmnaG609G/G609G y Apoe-/-LmnaLCS/LCS 
SM22αCre. Además, TUDCA prolonga en un 35% la supervivencia de los ratones Apoe-/-
LmnaLCS/LCS SM22αCre con expresión de progerina específica en CMLVs. Estos resultados 
identifican la respuesta al estrés de RE y la UPR como un mecanismo clave en la inducción de 
muerte de las CMLVs y la aceleración de la aterosclerosis provocadas por progerina. 
 
En resumen, nuestros resultados con modelos de ratón progérico sugieren la posibilidad de 
tratamiento con chaperonas químicas para mejorar la aterosclerosis en niños con HGPS. Teniendo en 
cuenta que el envejecimiento prematuro y fisiológico comparten muchos mecanismos y patologías 
(incluyendo ECV), y que se han detectado niveles bajos de expresión de progerina en células y tejidos 
de individuos sin HGPS, nuestra investigación en HGPS podría arrojar luz sobre el envejecimiento 
normal. 
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